Synthesis of molecular probes for one-electron reduction

A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science

Department of Chemistry

Lakehead University

Thunder Bay, Ontario

Smerah Ayde Alharthi

2017

ABSTRACT

Controlled drug release plays an important role in medicine because it can be a factor in human health care. It is defined as the ability to release a drug inside the body at a specific time. Radiation-sensitive functionalized materials can be controlled by outside triggers such as radiation and have great potential for application in controlled and targeted drug delivery. Radiation-sensitive functional groups are known and studied, however, there are very few examples. Previous studies have revealed that 2-oxoalkyl group can successfully undergo radiolytic cleavage, but under relatively high doses of radiation. It is desirable that the radiolysis efficiency of 2-oxoalkyl group be improved in order to gain applications in clinical medicine. Thus, one objective of this thesis was to study the effect of a few substituents on the radiolysis efficiency of substituted 2-oxoalkyl groups. Therefore, a few molecular probes that contain an aryl 2-oxoalkyl group with substituted acetophenone of monoesters of adipic acid, and coumarin scaffold of monoesters of adipic acid have been successfully synthesized. These compounds were studied under X-ray radiation at various doses to assess the potential of selective cleavage of the aryl oxo-methyl ester linkage. The radiolysis studies showed that less than 10% of the ester linkages in these compounds were degraded under a dose of up to 20 Gy of radiation. Compounds were also studied for their hydrolytic rate for the aryl oxo-methyl ester linkage using TLC method. Hydrolysis at around neutral pH happened at a slower rate for compounds that are sterically more hindered at the oxo-methyl position.

Poly-L-glutamic acid (PGA) is a natural polypeptide that is biodegradable and biocompatible. Therefore, it has been exploited as drug carrier system. In this thesis, PGA has been modified with a phenacyl group. The lipophilic phenacyl group is assumed to assist the formation of nanoparticles for the modified PGA. Radiolysis studies of such modified PGA showed that the grafted phenacyl group can be selectively cleaved upon radiation with a clinically relevant dose.

Lawsone is a commercially available natural product. It has been used as starting material for the synthesis of different biologically active compounds. Lawsone also has various biological effects including anticancer activity. One anticancer mechanism of lawsone is associated with its ability to undergo one-electron reduction. Thus, another aspect of this thesis was to synthesize lawsone derivatives as potential anticancer agents. The preparation of glycosylated lawsone derivatives was of particularly interest. Direct glycosylation of lawsone using a number of methods was unsuccessful in providing fully deprotected lawsone glycosides. Then the Mannich reaction was employed to produce a group of lawsone derivatives including one compound bearing a glucose residue. The synthesized lawsone derivatives will be evaluated for anticancer activity in the future work.

ACKNOWLEDGMENT

I gratefully acknowledge to my supervisor Dr. Zi-Hua Jiang, for his support, guidance and understanding through my master studies. It was really a pleasure to work with him. My appreciation also extends to Dr. Christine Gottardo and Dr. Aicheng Chen. I would also like to thank Faculty of the department chemistry at lakehead. I am thankful to Debbie Puumala and Christina Richard at chemistry store for their kindness.

My thanks go out to Saudi ministry of higher education, and Saudi bureau in Ontario for financial supports.

 Finally, my deepest gratitude goes to my husband, Mufleh, and my parents for their support and encouragement and patience, which allowed me to achieve this work.

ABBREVATION

AcOH	acetic acid
Anal	analytical
BF$_3$OEt	boron trifluoride diethyl etherate
CHCl$_3$	chloroform
CNCCl$_3$	trichloroacetonitrile
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCM	dichloromethane
ddH$_2$O	double-distilled water
DIPCI	*N,N*-diisopropylcarbodiimide
DIPEA	diisopropylethylamine
DMAP	4-*N,N*-dimethylaminopyridine
DMF	*N,N*-dimethylformamide
DMS	dimethyl sulfoxide
Et$_3$N	triethylamine
EtOAc	ethyl acetate
Gy	gray
Hz	hertz
KI	potassium iodide
MeOH	methanol
MeONa	sodium methoxide
mg	milligram

min	minutes
mL	millitre
mmol	millimoles
m-PGA	modified poly-L-glutamic acid
NaH	sodium hydride
$NaHCO_3$	sodium bicarbonate
NMR	nuclear magnetic resonance
PGA	poly-L-glutamic acid
ROS	reactive oxygen species
rt	room temperature
s	singlet
t	triplet
THF	tetrahydrofuran
TLC	thin layer chromatography
TMS-Cl	trimethylsilyl chloride
TMS-I	trimethylsilyl iodide
UV	ultraviolet

Table of Contents

List of Figures

List of Schemes

List of Tables

1. Introduction

1.1. Cancer

The American Cancer Society reports that more than 1,500 people die each day due to cancer. Currently, radiotherapy, chemotherapy and surgery are the possible treatment options for cancer. Chemotherapy treatment involves drugs to treat cancer or relieve cancer symptoms. Often the combination of chemotherapy, radiotherapy and surgery is necessary and useful to overcome cancer. Radiotherapy and surgery are the localized therapies that work only when malignant cells are confined to the treated area. Thus, chemotherapy is crucial for the systemic treatment of metastases relating to the local and regional growth of tumors.[1]

The anticancer drugs used in chemotherapy are systemic anti-proliferative agents that prefer to kill the dividing cells. However, the prolonged use of chemotherapy results in lethal damage to proliferating normal cells along with the tumor cells.[2] Therefore, most chemotherapeutic agents suffer from low selectivity towards tumor cells, and low therapeutic index. The side effects diminish the extent of the dose that can be administered to treat tumors. [3]

1.2. Anti-cancer drug delivery

Novel drug delivery systems aim at increasing the benefit of drugs and decreasing side effects, [4] with a goal of increasing their pharmacokinetics and their biodistribution.[5] Anticancer drugs in conventional chemotherapy are not specific or targeted to the cancer cells; therefore,

targeted delivery of anticancer drugs to cancer tissues is being developed to meet the challenge.[6]

Drug delivery systems can increase the bioavailability of drugs by entrapment of the drugs within a suitable carrier such as liposomes and micro/nanoparticles of natural or synthetic polymers.[7] Therefore, the objective of all drug delivery system is to distribute medications to specific body parts through an agent that can control drug bioavailability by a physiological or chemical trigger.[8] To achieve this goal polymeric microspheres, polymer micelles and hydrogel-type materials have been demonstrated to improve drug targeting specificity, decreasing the drug toxicity, decreasing dosing frequency, and offering protection against biochemical degradation, which results in increasing treatment success rates.[7]

1.3. Prodrug approach

To improve the therapeutic activity and reduce the side effects of current anticancer drugs, anticancer prodrugs have to be developed. Prodrugs are advantageous in affecting tumor cells and safe to normal cells.[3] The design of a prodrug aims to make the active drug work on the specific spot, to offer the necessary pharmacological impact, and to limit side effects.[9]

Consequently, the goal of prodrug design is to temporarily change the physicochemical properties of drugs in order to modify drug pharmacokinetics, prolong action, decrease toxicities and side effects, enhance selectivity, and solve challenges related to formulation.[10] This can be achieved by a variety of mechanisms that include hypoxic reduction in solid tumors, activation by enzymes overexpressed in tumor tissues, and targeting of antigens or receptors specifically expressed on tumor cell surface.[3] Therefore, using targeted anticancer

prodrugs for tumor spot selective activation is an effective approach for improving chemotherapy.[11]

1.4. Stimuli-responsive polymers in drug delivery

New polymers are now being developed that are able to act in response to their environment by changing their physical and chemical properties.[12] These polymers have been designed to respond to various types of stimuli, such as pH, temperature, mechanical force, various small molecules and biomolecules that are present, as well as electric/magnetic fields. As a result, the polymers are called "stimuli-responsive polymers" or "smart/ intelligent polymers". [12] For example, pH-responsive polymers can be reversibly manipulated by changes in external pH. This approach can be used for anticancer drug delivery since for most tumors' the extracellular pH is more acidic (5.8-7.2). Thus, the release of a drug can be initiated via manipulating the pH.[13] Another example of stimuli-responsive systems is a photo-responsive system that uses light. This can be utilized in polymer chemistry as an energy source for polymer synthesis, as well as an information source or a trigger, controlling reversibly the physical and chemical properties of polymers.[14]

1.5. Radiation-sensitive functional groups

Very few radiation-sensitive functional groups are known and have been studied. Consequently, a radiation-responsive drug delivery system is rarely studied. One functional group that has been reported to undergo radiolytic cleavage is the 2-oxoalkyl group. Some studies reveale that the carbonyl group positively affected the release of the leaving group X (Scheme 1) through

one-electron reductive pathway.[15] Antitumor drugs such as, fluorodeoxyuridine (5-FdUrd) that are toxic to normal cells as well as to tumor cells have been connected to 2-oxoalkyl groups to make prodrugs that can be activated through radiation.[16] Exposure to radiation can be controlled and so, much like a prodrug, the radiolytic drugs can become active in a specific area, during a particular time, and with a specific dosage.[15]

An activation mechanism (Scheme 1) has been proposed, in which one-electron is absorbed, and can enter to the π^* of the double bond (**b**). Moreover, by thermal activation the electron in the π^* can enter into the σ^* (**c**) that leads to a weakened σ bond that can cleave readily (**d**). Without the 2-oxoalkyl groups, the reaction does not continue. Furthermore, under aerobic conditions, this reaction does not happen[17] because the oxygen can prevent radiolytic reduction and make a superoxide anion radical.

Scheme 1: Proposed mechanism for one-electron reduction.

Another molecule, indolequinone was studied for its radiolytic cleavage as well as bio-reductive cleavage. Activation of the indolequinone **(e)** under reductive conditions results in the formation of hydroquinone **(f)** or the semiquinone radical **(g)**. This reaction may occur under hypoxic condition resulting in the reduction by one-electron or by two-electron reducing enzymes, and these reactions, along with the effect of oxygen on leaving group to produce **h** and **i**, were studied (Scheme 2).[18]

15

Scheme 2. Pathway of indolequinone reduction[18]

There are several other functional groups in which the reductive cleavage of a leaving group has been observed/assumed to occur in biological systems through enzymatic processes. The functional groups studied include nitrobenzyl **(j)**, nitroimidazolyl **(k)** and benzoquinone **(l)** as shown in Figure 1. The nitrobenzyl can cleave upon one-electron reduction in under hypoxic conditions. This reactivity has been reported in biological systems

and enzyme-catalyzed processes. Nitroimidazolyl showed that it can increase its cytotoxicity and hypoxia selectivity in radiotherapeutic outcome *in vivo.* In addition, benzoquinone activation has the ability to release a drug.[11]

Figure 1. Structures of nitrobenzyl group **(j)**, nitroimidazolyl group **(k)**, and benzoquinone group **(l)**

1.6. Poly-L-glutamic acid (PGA)

In recent years biocompatible polymers gained much attention in the research community. These macromolecules have specific pharmacokinetic characteristics, such as prolong blood circulate, strengthening retention of tissues; along with creating advantageous accumulation in lesions that have leaky vasculature.[19] Consequently, polymers have become useful drug delivery tools. Moreover, the fusion of small molecular weight anticancer agents to biocompatible polymers can enhance drug deposition at the tumor site and decrease dangerous outcomes of the drug on normal tissues.

For instance, poly-L-glutamic acid is a useful carrier of cancer therapeutics and imaging agents.[20] Poly-L- glutamic acid polymers can be conjugated to anti-oxidative agents without

impacting the pharmacological properties of the drugs. Due to such characteristics, these polymers have potential as renal targeting drug carriers.[21]

Poly-L-glutamic acid is a polypeptide made up of L-glutamic acid. It has two forms, poly-α-L-glutamic acid and poly-γ-L-glutamic acid according to whether the α or γ carboxy group is involved in the formation of the peptide bond. Their structures are shown in Figure 2. [22] Poly-γ-L-glutamic acid is a naturally-occurring polymer which can be isolated from bacteria, especially those of *Bacillus* species, or from a traditional food in Japan called Natto.[23] The application of poly-γ-L-glutamic acid has been increasing rapidly due to its ability of being biodegradable, edible and non-immunogenic.[22]

Poly-α-L-glutamic acid, which will be referred to in this thesis later on as poly-L-glutamic acid (PGA), is made up of naturally occurring L-glutamic acid monomers bonded to each other with amide bonds. In this polymer, L-glutamic acid monomers are connected between the α –carboxyl and the α -amino groups of adjacent monomers. [24] The pendant free γ carboxyl group in each repeating unit of L-glutamic acid carries a negative charge at a neutral pH. As a result, the polymer becomes slightly water-soluble. The carboxyl groups facilitate chemical modification of the polymer or drug attachment.[20] PGA is also biodegradable and biocompatible, which can be degraded by lysosomal enzymes.[25]

Poly-α-L-glutamic acid   Poly-γ-L-glutamic acid

Figure 2. Structures of poly-α-L-glutamic acid and poly-γ-L-glutamic acid

These characteristics make PGA the right factor for polymer–drug conjugates that can be used for selective delivery of chemotherapeutic agents. A number of antitumor agents including doxorubicin, daunorubicin, 1-β-D-araninofuranosylcytosine (Ara-C), uracil and uradine, cyclophosphamide, L-phenylalanine mustard, as well as mitomycin C, have been conjugated to PGA .[20] Virtually all of these PGA conjugates have led to better antitumor activity than the parent drug.[20] We are interested in the modification of PGA with functional groups that could be cleaved by a dosage of radiation.

1.7. Quinones

Many drugs currently contain the quinone functional group.[26] Quinones are very important in chemistry and biochemistry.[27]

There are two major mechanisms that are behind the cytotoxic and anticancer characteristics of the natural quinone structure. Several enzymes can reduce quinone to hydroquinone, which results in the formation of a fully aromatic system.[11] The first pathway, through the one-electron reduction, provides the semiquinone radicals via reductive enzymes such as cytochrome P450 reductase and NADH dehydrogenase. The other pathway occurs through a two-electron

reduction pathway to produce hydroquinone via reductive enzymes such as DT-diaphorase (Scheme 3). [28]

Scheme 3: Pathway of quinone reduction [29]

One of the active compounds in biology is 1,4-naphthoquinone. Naphthoquinones are widely available in nature; they are often found in bacteria, fungi, and in several plants.[29] 1,4-Naphthoquinone is often found in a genus of *Diospyros* L., which is the largest genus in the Ebenaceae family of plants that includes around 500 species. This genus appears in both tropical and temperate regions.[28]

Figure 3. Naphthoquinone structure

The efficacies of these compounds against tumor cells have been shown by various studies that have demonstrated various modes of action. For example, a study indicated that a natural benzoquinone derivative had enhanced anti-proliferative and apoptotic activities against human hormone-refractory prostate cancer cells (PC-3 and DU-145). [24] These compounds need reductive activation in order to form electrophilic species that are toxic to cells. Furthermore, the drugs act as substrates for the reductases found in most of the cells. These drugs can address solid tumors with defined hypoxic fractions and tumor tissues with the activating enzymes. [18]

The bioreduction of naphthoquinones is affected by their redox properties; the ability of these compounds to accept electrons can be changed by adding substituents. Thus, the substituents become electron acceptors or donors to the naphthoquinone rings. [30]

1.7.1 2-Hydroxy-1,4-naphthoquinone (lawsone)

One of the naturally occurring naphthoquinones is lawsone, also called 2-hydroxy-1,4-naphthoquinone (Figure 4). Lawsone is responsible for the red dye of henna. In some countries, henna is used for coloring hair, as well as dying nails and skin. In addition, it has some medicinal benefits. For example, it can be used to treat burns. [31] Henna also have a positive effects on treating microorganisms, headaches, lumbago, bronchitis, ophthalmic, syphilitic sores and amenorrhoea. [32] They also have antibacterial properties. The most important benefit of lawsone is its anticancer property. Lawsone prevents the development of cancer and inhibits cancer cell growth. Thus, this compound can be helpful in developing various drugs for fighting cancer or targeting other types of conditions as mentioned above. [32]

Figure 4. Lawsone structure

The majority of lawsone's biological activity arises from and can be explained by the redox cycling and alkylating properties lawsone possesses.[33] Through oxidation or alkylation of cellular structures, lawsone targets and damages the cells, potentially causing their death. This element is exploited during the use of lawsone in cancer therapy. In this case, cancer cells are more susceptible to oxidative damage as compared to their non-cancerous counterparts. Thus, lawsone can be used to kill the cancerous cells while sparing the non-cancerous ones.[33]

1.7.2 Redox properties of lawsone

In the treatment of cancer, the redox cycling is important to the metabolism of lawsone.[34] The quinone function of lawsone can be reduced to the semiquinone and thus to the hydroquinone through a chain of two one-electron reductions (Scheme 4). These species are reoxidized by molecular oxygen (O_2) and create reactive oxygen species (ROS), such as superoxide, hydroxyl radical and hydrogen peroxide.[29] The superoxide radical is a very reactive species and it is unstable. This instability results in the formation of hydrogen peroxide, which is toxic to cells because it can permeate membranes. ROS are dynamic-oxidizing agents and they

can most likely damage macromolecules such as DNA, proteins and lipids. Thus, ROS can lead to oxidative stress and apoptosis in the cells.[29]

Scheme 4: Redox properties of lawsone [29]

1.7.3 Preparation methods for lawsone

The synthesis 2-hydroxy-1,4-naphthoquinone has been derived through two main methods: 1) by ring construction or 2) by the use of naphthalene derivatives as starting materials.[32]

The first method involved the compound 3-methyl-1H-indane, which was oxidized by sodium dichromate, - converted to phenylacetic acid and cyclized to produce lawsone as shown in Scheme 5. [35]

Scheme 5. Preparation of lawsone [33]

The other method was achieved by using the economical naphthalene. Some examples of the most useful starting materials for making lawsone (Scheme 6) are examined below. 1-Amino-2-naphthol which is one of the starting materials, has been used with sodium bisulfite in aqueous 6N sodium hydroxide to produces 1-amino-2-napththol-4-sulfonic acid, which upon hydrolysis with concentrated sulfuric acid in methanol, leads to 2-methoxylawsones.[32] β-naphthol is another example of the starting material that is converted into β-naphthoquinone which reacts with acetic anhydride-sulfuric acid to produce 1,2,4-trihydroxynaphthalene triacetate, which is then hydrolyzed and oxidized into the desired lawsone.[36]

Scheme 6. Other methods used to prepare lawsone [32]

1.8. The benefits of using sugars in anticancer drugs

24

The anticancer agents conjugating with sugar residues have received a lot of attention in recent years. Unlike normal cells, cancer cells have the ability to accept larger amount of glucose as explained by the Warburg effect.[37] Glycoconjugation means linking a drug to glucose or other sugar in order to improve cancer targeting and selectivity.[38]

Some anticancer drugs contain glycosylated natural products. For example, Digoxin is a well-known glycoside drug that has anticancer activity.[39] The most important features of the sugar moieties present are increased water solubility, and thus the enhanced bioavailability of such compounds.

Figure 5. Digoxin structure [39]

Over-expression of glycolytic enzymes and insulin-independent glucose transporter GLUT-1 mediates the effect, which has been recognized as a hallmark of cancer development. [37] The idea of using glucose as cancer targeting molecular tool has been exploited. Several studies have shown that antitumor drugs bearing glucose residues display improved cancer selectivity compared to normal cells as well as decreasing toxicity of the drugs.[38]

1.9. Objectives

Currently, the aim of cancer research is to design a drug that is made up of cytotoxic compounds that selectively interact with molecules and target tumor cells with minimal toxicity to normal cells.

In this thesis we are going to study two separate yet related research topics: one is the radiolytic cleavage of aryl-substituted 2-oxoalkyl groups through one-electron reduction process induced by radiation; and the other is the synthesis of naphthoquinone derivatives that are potential anticancer agents after activation through one electron biochemical reduction. Thus, the following specific objectives of the thesis are identified. First, a group of molecular probes containing an aryl-substituted 2-oxo group will be synthesized for radiolytic studies aiming to improve radiolytic efficiency. Second, the biocompatible poly-L-glutamic acid (PGA) will be modified with a radiation-labile functional group to produce radiation-sensitive nano-materials. Third, a group of lawsone derivatives will be synthesized as potential anticancer agents.

2. Results and discussion

2.1. Radiation-sensitive molecular probes

2.1.1. Synthesis of molecular probes for radiolysis study

Radiation–sensitive functional groups can respond to X-ray or gamma ray radiation and undergo selective cleavage of certain bond. The 2-oxoalkyl group has been reported to undergo radiolytic cleavage. In addition, this group is removed by X-ray radiation under hypoxic conditions in an aqueous solution. [40] Under hypoxic conditions, X-ray radiation produces hydrated electrons, as well as hydrogen radicals and hydroxyl radicals in an aqueous medium. [40]

$$H_2O \xrightarrow{\text{X-radiation}} H^{\bullet} + O\overset{\bullet}{H} + e_{(eq)}$$

One problem associated with the radiolytic cleavage of 2-oxo-alkyl group is that it needs a relatively large dose of radiation; however, we are hoping to achieve te cleavage of such a group under clinically relevant radiation doses (< 30 Gy).

According to the proposed radiolysis mechanism of 2-oxo-alkyl group (Scheme 7), this radiolysis rate may be affected by the following factors:

a) The ease of the compound in absorbing electron(s)

b) The leaving ability of the leaving group

c) The stability of the free radical generated after the cleavage of the bond.

Scheme 7. The mechanism for one-electron reduction.

Previous studies have shown that an aromatic functionality in the neighboring environment of the 2-oxo-alkyl group can accelerate its radiolytic cleavage.[16] Here we anticipate that an aromatic ring directly linked to the 2-oxo-alkyl group may be able to enhance its radiolytic rate. In order to improve the radiolytic efficiency of 2-oxo-alkyl group, we plan to attach an aromatic ring to the 2-oxo-alkyl group. According to the proposed activation mechanism (Scheme 7), structure **m** can absorb one electron which can enter into the π^* of the C=O double bond. By thermal activation the electron in π^* can enter into the σ^*, which leads to a weakened σ bond that can cleave readily. The aryl functionality in the aryl 2-oxo-alkyl group is assumed to facilitate the fast capture of electron(s) and the stabilization of free radical species (**n** - p). These features are expected to result in a faster radiolytic cleavage of the aryl 2-oxo-alkyl group than the simple 2-oxo-alkyl group. The relative stability of the initial free radical (**p**)

28

generated from the radiolytic cleavage probably plays an important role in the final step of the cleavage. Since free radicals display the following trend of stability: $3^o > 2^o > 1^o$, alkyl substitutes at the carbon atom next to the oxo-group will stabilize the free radical and consequently accelerate the cleavage of the C-X bond in structure (**p**).

A group of molecular probes (**1** - **6**, Figure 6) have been designed to study the effect of these structure features on the radiolysis rate of aryl 2-oxo-alkyl group. Structures **1** - **5** are derivatives of simple acetophenone or substituted acetophenone and structure **6** contains a coumarin scaffold. All these molecules are monoesters of adipic acid. We are going to study poly-L-glutamic acid (PGA) modification, which has multiple carboxylic acid groups. Therefore, we have designed those molecular probes having one carboxylic acid functional group to resemble L-glutamic acid residues of the polymer. The carboxylic acid group in these probes will also make these molecules more hydrophilic and increase their water solubility.

1 R=R$_1$=H
2 R=H, R$_1$=CH$_3$
3 R=Ph, R$_1$=H
4 R=H, R$_1$=Ph

5

6

Figure 6. Designed molecular probes

For the preparation of probes **1** – **4**, adipic acid was reacted with one equivalent of a bromoacetophenone derivative (**7a**, **7b**, **8a**, and **8b**) in triethylamine (Et$_3$N) and EtOAc at room temperature to provide monoester (**1** - **4**) in 20% to 60% yield (Scheme 8). The corresponding diesters (**9** – **12**) were also obtained as the minor product for each of these reactions. The structures of these products were confirmed by ^{1}H NMR and ^{13}C NMR spectral data.

7a R=R$_1$=H
7b R=H, R$_1$=CH$_3$
8a R=Ph, R$_1$=H
8b R=H, R$_1$=Ph

1 R=R$_1$=H 20%	**9** R=R$_1$=H 9%
2 R=H, R$_1$=CH$_3$ 48%	**10** R=H, R$_1$=CH$_3$ 30%
3 R=Ph, R$_1$=H 19%	**11** R=Ph, R$_1$=H 7%
4 R=H, R$_1$=Ph 60%	**12** R=H, R$_1$=Ph 10%

Scheme 8. Synthesis of designed compounds (**1** - **4**)

For the preparation of probe **5**, we did not use the reagent 2-bromo-2 methylpropiophenone to react with adipic acid. It is likely that the bromide would react with the acid via an S$_N$2 mechanism, which is anticipated to be very slow for this 3° bromide. Therefore, we tried to form this ester through an acid and alcohol as shown in Scheme 9. This reaction happens through a mechanism of Steglich esterification reaction. The synthesis of **5** and **14**

was started with 2-hydroxy-2-methylpropiophenone that was combined with adipic acid, 4-*N,*

N-dimethylaminopyrdine (DMAP) and *N, N*–diisopropylcarbodiimide. The reaction was first

tried in dimethylformamide (DMF) as solvent at either room temperature or 50℃, but it gave

mixed products that was difficult to purify. Changing the solvent to dichloromethane (DCM) at

room temperature provides the desired product (**5**) in 19% yield and the corresponding diester

(**14**) in 21% yield. Their structures were also confirmed by ^{1}H NMR, and ^{13}C NMR data.

Scheme 9. Synthesis of probe **5**

Probe **6** contains a coumarin scaffold which can be viewed as an extended aryl system

with fluorescent property. For the preparation of **6**, adipic acid was reacted with 3-

(bromoacetyl)-coumarin in the presence of triethylamine as the base at room temperature.

However, the reaction was not efficient and the product was an inseparable mixture as TLC

showed. Changing the base to sodium bicarbonate was attempted; TLC investigations

revealed that the reaction did not occur either at room temperature or under reflux. However,

using *N,N*,diisopropylethylamine (DIPEA) in EtOAc as the solvent under reflux temperature gave successfully the desired product **6** in 17% yield. The diester (**16**) was also formed in small quantity (2% yield) in this reaction. The structures of these compounds were confirmed by ^{1}H NMR, and ^{13}C NMR.

Scheme 10. Synthesis of molecular probe **6**

2.1.2. Synthesis of tyrosine derivatives

The 2-oxoalkyl group has been reported in the literature to undergo radiolytic cleavage when it is linked to a leaving group. One particular example is a tyrosine derivative in which the 2-oxoalkyl group is connected to the phenolic hydroxyl group (**19**, Scheme 11). [16] Under hypoxic conditions, the 2-oxopropyl group in **19** can be released by radiolytic one-electron reduction.[16] Here we repeated the synthesis of **19** according to the published procedure.[16] Compound **19** is to be used as a positive control for the radiolytic studies of the synthesized molecular probes (**1** – **6**, Figure 6).

Scheme 11. Synthesis of tyrosine derivatives

2.1.3. Synthesis of cholesterol derivatives

A cholesterol fragment is a large hydrophobic group, and not toxic. It has been widely used as a lipophilic tag to modify biologically interesting molecules.[41] When cholesterol is incorporated with radiation sensitive groups, large structural changes due to large increase in lipophilicity can be expected for the molecule being modified.

Here we prepared cholesterol derivative **21** with an acid functionality (Scheme 12). The

synthesis of **20** was started with solution of sodium hydride in tetrahydrofuran stirred at room temperature then followed by adding cholesterol and *tert*-butyl bromoacetate. The mixture was stirred at 80℃ to provide **20** in 67% yield. Then, **20** was dissolved in DCM and treated with trifluoroacetic acid-water (95:5) at 0℃ to provide **21.**

Compound **21** can, in theory, be linked to a radiation sensitive group, such as the group containing an aryl 2-oxo-alkyl moiety. However, since the synthesized probes (**1** - **6**) did not show favorable radiolytic properties (see section 2.1.5), the idea of incorporating the cholesterol moiety into the radiolytic group was not further investigated.

Scheme 12. The synthesis of cholesterol derivative

2.1.4. Synthesis of modified poly-L-glutamic acid (PGA)

Poly-L-glutamic acid (PGA) is a biocompatible polymer that shows great potential as

drug carrier. Each side chain of the amino acid residues in PGA has one free carboxylic acid

group which is the basis for chemical modification. Modification of PGA with a lipophilic group can produce modified PGA (m-PGA), which may facilitate the formation of nanoparticles suitable for drug delivery. In addition, when the lipophilic group contains radiolytically labile chemical linkage(s), such m-PGA will be responsive to radiation. Drug carriers comprising of such radiation-sensitive material can achieve controlled drug releases upon activation by radiation. Towards this end, we have prepared a couple of m-PGA products modified with phenacyl group.

The commercially available PGA sodium salt was treated with HCl (pH = 1) to give the acid form of PGA (Scheme 13). PGA was then treated with phenacyl bromide and triethylamine (Et$_3$N) in dry DMF at 40°C to provide modified PGA. By using different amounts of reagents, one could achieve different degrees of modification. Table 1 summarizes two reaction conditions and the corresponding product details. Upon the completion of the reaction, the product was precipitated out by adding hexane-ethyl acetate (1:1, v/v), washed, and collected after centrifuge. The recovered yield of the material is typically over 80% according to this procedure (entry 1 in Table 1). However, ^{1}H NMR spectral data of the product m-PGA-Ph-24 indicates the presence of triethylamine, presumably in the form of HBr salt and/or carboxylic acid salt of the glutamic acid residues. In order to remove triethylammonium salt, the work-up procedure of product m-PGA-Ph-32 (entry 2, Table 1) was modified. The initial product obtained from the procedure described earlier was re-dissolved in DMF and then re-precipitated out from water. ^{1}H NMR spectral data of m-PGA-Ph-32 indicates that the triethylammonium salt is no longer present.

The structures of m-PGA were all confirmed by ^{1}H NMR spectral data. Typically, a proton signal at around δ 5.5 ppm corresponds to the CH$_2$ residue of the phenacyl group and

the signal at around δ 4.8 ppm resulted from the proton at the α-carbon of the glutamic acid

residue. The integration ratio of these two signals can be used to calculate the % of side chain

residues that have been modified.

Scheme 13. Preparation of modified poly-L-glutamic acid (m-PGA).

Table 1. Reaction conditions and product details of PGA modification.

Entry	Phenacyl bromide (equiv.)	Et$_3$N (equiv.)	Reaction Time (h)	Product	Degree of modification (%)	Recovery yield (%)
1	0.3	0.3	16	m-PGA-Ph-24	24	85
2	0.4	0.4	16	m-PGA-Ph-32	32	61

2.1.5. Radiolytic studies of synthesized probes

The radiolysis data for sections 2.1.5 and 2.1.6 were provided by our collaborator Dr. Wilson

Roa at Cross Cancer Institute & the University of Alberta, Edmonton, Alberta, Canada.

The synthesized probes (**1**, **2**, **4** and, **5**) were subjected to X-ray radiation at different

doses to evaluate the potential of selective cleavage of the aryl oxo-methyl ester linkage[15,16]

while compounds **3** and **6** were not determined because these two compounds were prepared after the evaluation of other compounds had been completed. After irradiation, the concentration of the original compound in each sample was measured by HPLC after 24 h and the results are summarized in Table 2. The data indicates that less than 10% of the sample was degraded when each of the probes was treated with X-ray radiation at a dose up to 20 Gy. The value in parenthesis indicates the % of decrease (–) or increase (+) of the concentration after irradiation relative to the control. Although compound **1** (having 8.5% degradation at 5 Gy) appears to have a higher degree of degradation than other compounds, the relatively low % of cleavage does not make such comparison meaningful. Thus, the structural influence on the radiolysis rate cannot be concluded based on these preliminary data.

Table 2. Change of sample concentration of probes (**1**, **2**, **4**, and **5**) after X-ray irradiation

Compound	Concentration (mg/mL) (±%)			
	Dose 0 Gy	Dose 5 Gy	Dose 10 Gy	Dose 20 Gy
1	0.684	0.626 (– 8.5)	0.649 (– 5.1)	0.648 (– 5.3)
2	0.621	0.584 (– 6.0)	0.607 (– 2.3)	0.605 (– 2.6)
3	Nd	nd	nd	Nd
4	0.657	0.606 (– 7.8)	0.631 (– 4.0)	0.628 (– 4.4)
5	0.530	0.534 (+ 0.01)	0.556 (+ 4.9)	0.557 (+ 5.1)
6	Nd	nd	nd	Nd

nd: not determined.

Compound **1** was also subjected to radiation under a much higher dose. Table 3 shows the sample concentration changes as a result of X-ray radiation under different doses. Again, the value in parenthesis indicates the % of decrease (–) or increase (+) of the concentration after the irradiation relative to the control. Radiation at a dose up to 200 Gy led to only about 6% of the sample being degraded. The data indicates that radiolytic cleavage is not significant even at a radiation dose that is much higher than the clinically relevant dose. For comparison purpose, compound **19** (Scheme 11) was also subjected to radiolysis study along with compound **1**. The results indicated that only a small percentage (< 10%) of compound **19** underwent radiolytic cleavage under the radiation dose of up to 200 Gy (data not shown). This is in contrast to the report earlier that the same compound **19** underwent about 30% selective radiolytic cleavage at an radiation dose of 150 Gy.[16] It is speculated that the experimental condition for radiolysis studies in our collaborator's lab has not been optimized. Radiolysis studies need to be repeated with these probes when the experimental conditions have been modified.

Table 3. Concentration change of compound **1** after X-ray radiation at different doses

X-ray dose (Gy)	C1 (μg/mL)	C2 (μg/mL)	C (average, μg/mL) (±%)
0	10.33	10.18	10.26
20	10.52	10.40	10.46 (+ 1.9)
100	9.87	9.69	9.78 (– 4.7)
200	9.96	9.79	9.88 (– 3.7)

At this point the radiolysis data for these synthetic probes are still preliminary results. It is still under investigation to determine the optimal experimental conditions for radiolysis studies. More experiments are needed in order to optimize the experimental conditions and fully characterize the degradation products.

2.1.6. Radiolytic studies of modified PGA

The m-PGA samples were subjected to X-ray radiation to study their radiolytic properties. Typically, an m-PGA sample was first dissolved in dimethylsulfoxide (DMSO) and then dd-H_2O was added. The resulting suspension was centrifuged, washed with dd-H_2O and then re-suspended in dd-H_2O for radiolysis study[15]. The sample was radiated with X-ray radiation (200 kV, 15 mA) at a dose up to 30 Gy. The phenacyl group cleaved from m-PGA resulted in some aromatic compounds that were extracted with EtOAc and analyzed with UV spectroscopy. The UV absorbance was used to show the radiolysis effect. Figure 6 shows the radiolysis effect of one specific m-PGA under the dose of 5 Gy, 10 Gy or 30 Gy. The data shows that X-ray radiation significantly increases the cleavage of the phenacyl group in m-PGA. The fact that the control sample without radiation (0 Gy) also produces UV-absorbance suggests that auto-hydrolysis of the phenacyl ester group might have occurred to some extent, which requires further study to confirm.

Figure 7. X-ray radiolysis result of m-PGA

2.1.7. Hydrolysis studies of synthesized probes

Radiolysis studies with m-PGA samples suggest that the phenacyl ester bond might undergo auto-hydrolysis. The substitution at the α-position of the carbonyl group (R_1 and R_2) may increase the rate of radiolytic process but slow down the auto-hydrolysis rate of the ester linkage under physiological condition. In order to understand the effect of different substituents on the relative stability of phenacyl esters, we have qualitatively investigated the hydrolysis rate of molecular probes (**1**, **2**, **4** and **5**, Figure 8).

1 R=R$_1$=R$_2$= H
2 R=R$_1$=H, R$_2$=CH$_3$
4 R= R$_1$= H, R$_2$= Ph
5 R=H, R$_1$=R$_2$=CH$_3$

Figure 8. Structures of probes for hydrolytic studies

The hydrolysis rate of molecular probes (**1**, **2**, **4** and, **5**) has been studied under 0.5 M

NaH$_2$PO$_4$/Na$_2$HPO$_4$ buffer solution (pH 7.0) at room temperature (22°C) using qualitative TLC

(thin layer chromatography) analysis. The chemical reaction is shown in Scheme 14 and TLC

was used to monitor the progress of the reaction. Results are presented in Figure 9. The

hydrolysis of **1**, **2**, **4** and **5** yields the corresponding aromatic alcohol **1a**, **2a**, **4a** and **5a** as the

hydrolyzed product (Scheme 14), which can be readily detected by UV absorbance or

staining. The relative intensity of the product spot to the starting material spot indicates the

degree of hydrolysis in each case. The TLC data indicate that compounds **1** and **2** are

accompanied with significant hydrolysis after four to five days under the above conditions. On

the other hand, hydrolysis is not significant for compounds **4** and **5** after stirring for two weeks

under these conditions. The results indicate that steric hindrance at α-position of the carbonyl

group can slow down the rate of auto-hydrolysis.

1 R=R$_1$=R$_2$= H
2 R=R$_1$=H, R$_2$=CH$_3$
4 R= R$_1$= H, R$_2$= Ph
5 R=H, R$_1$=R$_2$=CH$_3$

1a R=R$_1$=R$_2$= H
2a R=R$_1$=H, R$_2$=CH$_3$
4a R= R$_1$= H, R$_2$= Ph
5a R=H, R$_1$=R$_2$=CH$_3$

**Scheme 14**. The potential hydrolysis of molecular probes **1**, **2**, **4** and **5**

Figure 9. TLC results of the hydrolysis reaction of molecular probes **1, 2, 4** and **5** under pH 7 at 22°C with (hexane / ethyl acetate/ methanol = 1:1:0.2). SM: starting material; P: hydrolysis product (**1a**, **2a**, **4a** and **5a**); Salt of SM: the sodium salt form of the starting material; on each TLC plate, the first column represents the pure starting material dissolved in ethyl acetate. The second column represents the mixture of the starting material and the reaction medium. The third column represents the reaction medium.

2.2. Synthesis of lawsone derivatives

Lawsone (2-hydroxy-1,4-naphthoquinone) has the orange-red colour artefact that makes through the extraction or preparation of the dye from henna leaves.[42]

Lawsone is structurally related to naphthalene and characterized by its two carbonyl groups at the 1,4-position, and as such, are named 1,4-naphthoquinone. Carbonyl groups may also be present at the 1,2-position, with minor incidence. [29]

1,4-diketone   1,2-diketone

Lawsone has various biological activities such as, antioxidant, anti-inflammatory, antibacterial and anticancer activities.[43] This is the reason why this type of natural organic compounds is attractive in different areas of research. Lawsone has been used as a starting material in the synthesis of many clinically useful anti-cancer compounds such as atovaquone, lapachol and dichloroallyl lawsone. [44]

We are interested in the preparation of glycosylated lawsone derivatives since conjugation of a sugar residue may affect the physical, chemical and

biological properties of lawsone. As discussed earlier in Section 1.8, cytotoxic

drugs carrying a glucose residue may target cancer cells more selectively than

normal cells. Therefore, glycosylated lawsone derivatives may be useful

antitumor agents that have low toxicity to normal cells/tissue.[37]

2.2.1. Attempts to synthesize glycosylated lawsone

2.2.1.1. Synthesis of peracetylated glucosyl lawsone

The synthesis began with the protection of all OH groups in glucose with

acetic anhydride in the presence of pyridine at room temperature. This reaction

resulted in product **22**, which was found in one particular spot on the TLC.

Furthermore, removal of the acetyl group in the anomeric position was done in

one step. In this case, ammonium carbonate was utilized in anhydrous

dimethylformamide (DMF) to provide **23**; this compound needed to be purified by

chromatographic separation. **23** was then treated by trichloroacetonitrile with 1,8-

diazabicyclo[5.4.0]undec-7-ene (DBU) as catalytic base in anhydrous

dichloromethane to give **24** in 90% yield. This synthesis was carried out

according to a reported procedure with some modification.[45] Direct coupling of

glycosyl imidate **24** with lawsone **25** was achieved in anhydrous tetrahydrofuran

and dichloromethane with boron trifluoride diethyl etherate as the catalyst at

room temperature, to provide **26** in 65% yield. In addition, **27** was yielded in 18%.

Both compounds were confirmed by ^{1}H NMR and ^{13}C NMR data.

Scheme 15. Synthesis of peracetylated glucosyl lawsone derivatives

2.2.1.2 Attempts of deacetylation

To deprotect acetyl groups on the glucose residue of **26**, we used various basic conditions (Table 4), which led to an unexpected and undesired result of the cleavage of glycoside linkage (Scheme 16). First the removal of acetyl group in compound **26** by tetrahydrofuran (THF) and water in triethylamine (Et$_3$N) was unsuccessful and TLC showed the formation of **25**. A different base, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was also tried. This was done with toluene solvent or methanol solvent, which showed a similar result. Furthermore, guanidine-guanidinium nitrate (G/GHNO$_3$) has been reported to be a very mild and efficient method to remove acetyl groups. [46] Therefore G/GHNO$_3$ solution was prepared by using guanidinium nitrate in anhydrous MeOH/DCM and adding sodium methoxide (MeONa). Treatment of **26** with G/GHNO$_3$ resulted in the formation of 2-methyl-1,4-naphthoquinone **29** which was confirmed by [1] HNMR data.

Table 4. Conditions used in deacetylation reaction

	Reagent	**Temperature**	**Solvent**
I	Et$_3$N	rt.	THF + H$_2$O
ii	DBU	rt.	MeOH
iii	DBU	60 ^{o}C	Toluene
iv	Guanidinium + guanidinium nitrate + MeONa	rt.	MeOH/CH$_2$Cl$_2$

Scheme 16. Deprotection of acetyl group

This unexpected result can be explained by the possible mechanism shown in Scheme 17. Using the formation of **29** as an example, methanol functions as a nucleophile under weakly basic condition. First, a lone pair in methanol attacks through a simple nucleophilic addition to the α,β-unsaturated carbonyl system (a 1,4-addition reaction). The intermediate (**r**) then regenerates the carbonyl system with the OR group (sugar residue) functioning as a leaving group, leading to the formation of **29**. The formation of lawsone **25** in these deacetylation reactions would follow a similar pathway wherein H_2O is the initial nucleophile attacking the α,β-unsaturated carbonyl system followed by removal of the sugar residue.

Scheme 17. Proposed mechanism for the cleavage of glycosic bond

2.2.1.3. TMS protection strategy

Glycosylated lawsone with tetramethylsilyl (TMS) as the protecting group for the sugar OH groups was synthesized (Scheme 18). According to the known literature procedure [47], glucose was first protected via trimethylsilyl chloride with triethylamine

(Et$_3$N) in dimethylformamide (DMF) to provide the desired product **30** with 88%

yield. The protected compound **30** was treated by trimethylsilyl iodide in

anhydrous DCM, which gave **31** in 74% yield. Simultaneously, 1,4-hydroxy-

naphthoquinone **25** was reacted with sodium bis (trimethylsilyl) amide as base in

THF at room temperature to provide a mixture of **32** and **33**, which was further

reacted with **31** in the presence of 15-crown-5. The reaction produced a mixture

of products as indicated by multiple spots on TLC, presumably both **34** and **35**,

each of which as a β/α mixture. The mixture was not purified for structure

characterization since TMS ethers are pretty unstable.

Then, the product mixture (**34/35**) was subjected directly to deprotection in

order to obtain lawsone glycosides with free sugar (**36/37**) under various conditions

(Table 5). Unfortunately, all the trials were unsuccessful (Scheme 19). The first

method involved methanol under reflux. This condition led to the decomposition of

34/35 to form lawsone **25**, which was noted by TLC. Moreover, amberlite IRC-50, a

weakly acidic resin, in MeOH, was tried to achieve deprotection. This process gave

a similar result as the one mentioned above. In addition, amberlite IRC-120 (H$^+$

form) in MeOH provided 2-methoxy -1,4-naphthoquinone **29** which was confirmed

by ^{1}HNMR data. The formation of **25/29** under these conditions is probably via the

same mechanism as described in Scheme 17. TMS deprotection can generally be

achieved under weak acid or base condition; however, in this case it was not

successful.

Scheme 18. Attempted synthesis of glucosyl lawsone through TMS protection strategy

Table 5. Conditions used in deprotecting TMS groups

Reagent	Temperature	Solvent
i)	Reflux	MeOH
ii) amberlite IRC-50 resin	rt.	MeOH
iii) amberlite IRC-120 resin	rt.	MeOH

Scheme 19. The result of deprotection of TMS group

2.2.1.4. Attempted synthesis of C-glycosides of lawsone via aldol condensation reaction

When a ketone enolate or enol reacts with an aldehyde, the reaction is called an aldol condensation and forms a new C-C bond. Lawsone is a typical enol (Scheme 20). In fact, lawsone has been used to couple with an aldehyde to form similar aldol condensation type of product.[48] Through an aldol condensation lawsone can react with an aldehyde under mild conditions to give condensation product in very good yield.[32]

Scheme 20. Lawsone as an enol

A sugar (aldose) is an aldehyde in its open chain form. It can potentially react with lawsone to yield a C-glycoside of lawsone (Scheme 21). The reaction mechanism of this reaction is shown in Scheme 22. The reaction is expected to be catalyzed by a weak acid or base. Therefore, direct coupling of lawsone with glucose to give C-glycoside of lawsone has been tried under different conditions as shown in Table 6. Unfortunately, none of the conditions tried yields the desired product. Some reagents appeared to give new spots on TLC, but when purified only starting material lawsone was obtained. With beta-alanine conditions, a polar spot on TLC was detected, which might be alanine attached to

lawsone.

Scheme 21. Attempted synthesis of C-glycosides of lawsone

Scheme 22. Proposed mechanism for the formation of lawsone C-glycosides

Table 6. Reaction conditions tested for the formation of lawsone C-glycoside

Reagent	Temperature
$NaHCO_3$ / H_2O	rt. / 60 ^{o}C / 100 ^{o}C
NaOH / H_2O	rt. / 60 ^{o}C
H_2SO_4 / H_2O	rt. / 60 ^{o}C / 100 ^{o}C
AcOH / HCl / H_2O	80 ^{o}C
AcOH	80 ^{o}C / 100 ^{o}C
AcOH / H_2O (1:1)	80 ^{o}C / 100 ^{o}C
AcOH /Beta-alanine/ H_2O (3:1)	50 ^{o}C / 80 ^{o}C
AcOH + Beta-alanine	50 ^{o}C
Et_3N / THF	rt. / 69 ^{o}C
Aniline / AcOH / Absolute ethanol	rt. / 50 ^{o}C
Aniline/ AcOH/ imidazole / ethanol (1:1)	rt. / 50 ^{o}C
EtOH / H_2O (1:1)	rt. / 50 ^{o}C / 80 ^{o}C/ 100 ^{o}C
AcOH / DMF	100 ^{o}C
N, N-diisopropyl -ethylamine /DMF	rt. / 50 ^{o}C / 100 ^{o}C
$AcOH+H_2SO_4$	125 ^{o}C

2.2.2. Synthesis of lawsone derivatives via Mannich reaction

The Mannich reaction is one of the most useful reactions in organic chemistry, which has been utilized to form carbon-carbon bonds. This reaction is based on three components: an amine, an aldehyde, and an enolizable ketone,

which can produce β-amino carbonyl compounds.[28] These compounds are very valuable intermediates for the synthesis of many pharmaceutical and natural products containing nitrogen in their structures. Lawsone derivatives have been reported to be prepared through Mannich reaction.[49]

In this thesis, a group of lawsone derivatives (**45 – 49**) was produced by the Mannich reaction between lawsone, primary or secondary amine (ethanolamine, 3-amino-1-propanol, or diethanolamine), and an aldehyde (formaldehyde or benzaldehyde) in ethanol at room temperature in very good yield (Scheme 23, Table 7). The yields obtained were in the range of 82% to 98%. When the same reaction was tried with hexylamine and formaldehyde, TLC analysis indicated the formation of additional nonpolar spots, which complicated the isolation of the usual product. The structures of **45 – 49** were confirmed by ^{1}HNMR and ^{13}CNMR data.

Scheme 23. Synthesis of lawsone derivatives using Mannich reaction

Table 7. The ragents used to synthesize lawsone derivatives via Mannich reaction

	Aldehyde	Amines	Solvent	Product	Yield
45			ethanol		73%
46			ethanol		94%
47			ethanol		98%
48			ethanol		86%
49			ethanol		97%

Hence, the Mannich reaction worked successfully to attach lawsone to an aldehyde and an amine. Next, we tried to use Mannich reaction to attach lawsone with glucose (Scheme 24). First D-glucose was converted to the imidate **24** as described earlier (Scheme 15). Then, *tert*-butoxycarbonyl (Boc) group was used to protect the amine group in 3-amino-1-propanol by reacting with di-*tert*-butyl dicarbonate in presence of triethylamine in $CHCl_3$ to afford **50**. Compound **50** was ready to react with **24** in the presence of boron trifluoride diethyl etherate $BF_3O(Et)_2$ as the catalyst in dichloromethane to provide the desired product (**51**) in 14% yield. After that **51** was treated with sodium methoxide in anhydrous methanol to give the de-acetylated intermediate, which was then treated with trifluoracetic acid (TFA) - water (95:5) to remove the Boc group, affording **52**.

The glycosylated amine derivative **52** was reacted with lawsone in the presence of formaldehyde in ethanol at room temperature. The formation of **53** was not a very clean reaction as TLC showed multiple spots that was in contrast to those listed in Table 7. Flash chromatography had to be used to purify **53,** which was obtained in 15% yield. The structure of **53** was confirmed by ^{1}H NMR data. Signals found in both aromatic and sugar regions confirm that lawsone and glucose are connected.

Scheme 24. Synthesis of glycosylated of lawsone using Mannich reaction

3. Conclusion

An important element of health care is controlled drug release. In this case, a drug is released inside a person. This is a process that occurs at a specific time in a specific location. Outside triggers can control radiation-sensitive functionalized material, such as radiation. These materials can be utilized during controlled and targeted delivery of drugs. Radiation-sensitive functional groups are known and studied. However, very few examples of such groups exist. Earlier studies show that 2-oxoalkyl group has the capacity to go through a radiolytic cleavage. Here, we synthesized a group of molecular probes (**1** – **6**) that encompass aryl substituted 2-oxoalkyl groups. These molecular probes were

studied under X-ray radiation at various doses. This was done in order to determine the possibility of selective cleavage of the aryl oxo-methyl ester linkage. The hydrolytic rate of the ester linkage in molecular probes (**1**, **2**, **4** and **5**, Figure 6) was studied. TLC analysis of the hydrolysis reaction mixture indicated that hydrolysis occurred at a faster rate for **1** and **2** than for **4** and **5**.

Poly-L-glutamic acid (PGA) is a natural polypeptide. It is both biodegradable and biocompatible. As a result, it is being exploited for utilization as a drug carrier system. In this research, we modified PGA with the lipophilic phenacyl group in order to make radiation-sensitive nanomaterials. Preliminary experimental data show that the phenacyl groups grafted on the PGA can be selectively cleaved upon radiation with a clinically relevant dose (up to 20 Gy).

Lawsone is commercially available and it can be obtained from natural sources. Lawsone as starting material has been used for the synthesis of different biologically active compounds. Lawsone also has biological effects such as anticancer and antibacterial activity. In this study lawsone was used as a starting material to synthesize lawsone derivatives as potential anticancer agents. We are particularly interested in the preparation of glycosylated lawsone derivatives. Direct connection of lawsone to glucose through either *O*-glycosidic linkage or *C*-glycosidic linkage was unsuccessful using various conditions in this study. Through a Mannich reaction lawsone was successfully linked to various polar amines including a glycosylated amine to provide lawsone derivatives as potential anticancer agents. The structures of these lawsone derivatives were characterized by ^{1}H and ^{13}C NMR spectral data.

4. Future work

The first part of the research focuses on the synthesis of probes **1** - **6** to study the structure effects on radiolysis efficiency. However, the result of radiation study was not clear, therefore further studies are needed. For the modification of poly-L-glutamic acid, the phenacyl-modified polymer showed some indication of responsiveness to radiation. Therefore, more modifications of PGA can be done with different modifying groups. In the second part, the Mannich reaction works in providing glycosylated lawsone derivative **53**. The synthesis of **53** could be repeated to get more material and obtain other analytical data including ^{13}C NMR and mass spectrum data- due to time restrain, I was not able to complete this part of the work. All the synthesized lawsone derivatives (**45** – **49** and **53**) will be evaluated for anticancer activity. Furthermore, other glycosylated lawsone derivatives could be prepared using the Mannich reaction. A few examples are shown in Figure 10 for future research.

Figure 10. Glycosylated lawsone derivatives for future research

5. Experimental

5.1. General Methods

Thin Layer Chromatography (TLC) was performed on Silica Gel 60-F_{254} (Silicycle) with detection by quenching of fluorescence (254 nm), by dipping into 15% solution of H_2SO_4 and/or Mostaine reagent [ammonium molybdate $(NH_4)_6Mo_7O_{24}.4H_2O$ (20 mg) and Cerium (IV) sulphate $(Ce(SO_4)_2,0.4$ g) in 10 % sulphuric acid (400 ml)] followed by charring on hot heating plate.^{1}H NMR spectra were measured at 499.9 MHz (Varian Unity Inova 500 MHz). ^{13}C NMR spectra were recorded at 125 MHz on the same instrument. TMS (Me_4Si, 0 ppm) or solvent peaks were used as reference standard. Column chromatography was done on Silica Gel 60 (Silicycle 40-63 m). Elemental analyses were carried out on a CEC (SCP) 240-XAAnalyzer instrument by Lakehead University Instrumentation Laboratory (LUIL). All commercial reagents were used as supplied. Solvents for anhydrous reactions were dried according to literature procedures. Dichloromethane was distilled over calcium hydride, methanol was distilled over magnesium, and tetrahydrofuran was distilled over sodium.

5.2. Synthetic Procedures and Structure Characteristics

6-Oxo-6-(2-oxo-2-phenylethoxy)hexanoic acid (1) and bis(2-oxo-2-phenylethyl) adipate (9)

1   **9**

Et$_3$N (1.91 mL, 13.7 mmol, 1 eq.) was added to a solution of 2-bromoacetophenone (2.7 g, 13.7 mmol, 1 eq.) and adipic acid (2.0 g, 13.7 mmol, 1 eq.) in EtOAc (20 mL). The mixture was stirred at room temperature overnight. The solid was then filtered and washed using EtOAc. The filtrate was concentrated under vacuum and the residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 1.5:1, 1:1) to provide **1** (0.73 g, 20%) as a white powder and **9** (0.47 g, 9%).

For **1**: R$_f$ 0.34 (hexane / ethyl acetate 1:1); ^{1}H NMR: (500 MHz, chloroform-*d*): δ 7.98 −7.89 (m, 1H), 7.63 (m, 1H), 7.56 – 7.47 (m, 2H), 5.38 (s, 2H), 2.56 (m, 2H), 2.48 – 2.39 (m, 2H), 1.79 (br. s, 2H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 192.22, 179.54, 172.74, 134.14, 133.91, 128.86, 127.76,

65.96, 33.64, 33.47, 24.22, 23.99, 23.96.

For **9**: ^{1}H NMR (500 MHz, chloroform-*d*): δ 7.92 (dt, *J* = 8.4, 1.4 Hz, 4H), 7.66 – 7.57 (m, 2H), 7.50 (td, 4H), 5.36 (s, 4H), 2.56 (m, 4H), 1.88 – 1.78 (m, 4H). ^{13}C NMR (125 MHz, chloroform-*d*): δ 192.20, 172.73, 134.19, 133.86, 128.85, 127.75, 65.93, 33.50, 24.26.

6-Oxo-6-(1-oxo-1-phenylpropan-2-yl)oxy)hexanoic acid (2) and bis (1-oxo-1-phenylpropan-2-yl)adipate (10)

2   **10**

Adipic acid (1 g, 6.85 mmol, 1 eq.) was dissolved in EtOAc (20 mL) and Et$_3$N (0.95 mL, 6.85 mmol, 1 eq.) and bromopropiaphenone (1.46 g, 6.85 mmol, 1 eq.) was added. The reaction mixture was stirred at room temperature overnight. Usual work-up as described for the preparation of compound **1** followed by column chromatography on silica gel (hexane/ethyl acetate = 1.5:1, 1:1) provided **2** (0.92 g, 48%) as syrup and **10** (0.85 g, 30%). Compound **10** was not fully purified. A clean ^{1}H or ^{13}C NMR spectrum for **10** was not obtained.

For **2**: R$_f$ 0.6 (hexane/ethyl acetate 1:1); ^{1}H NMR (500 MHz, chloroform-*d*) δ10.5 (s, OH), 8.12 (s, 1H), 7.94 (dt, *J* = 8.6, 1.4 Hz, 2H), 7.59 (td, *J* = 7.3, 1.5

Hz, 1H), 7.48 (td, J = 7.8, 1.9 Hz, 2H), 5.97 (q, J = 7.0 Hz, 1H), 2.52 – 2.34 (m,

4H), 1.71 (m, 4H), 1.53 (d, J = 7.1 Hz, 3H). ^{13}C NMR: (125 MHz, chloroform-d) δ

197.02, 179.18, 172.75, 134.34, 133.60, 128.77, 128.44, 71.39, 33.52, 24.14,

23.95, 17.10. Anal.Calcd **2** for C_{15} H_{18} O_5: C, 64; H, 6.51. Found: C, 64; H, 6.54.

6-{2-[(1, 1'-biphenyl)-4-yl]-2-oxoethoxy}-6-oxohexanoic acid (3)

and bis (2-([1,1'biphenyl]-4-yl)-2-oxoethyl) adipate (11)

Adipic acid (1 g, 6.84 mmol, 1 eq.) was dissolved in EtOAc (20 mL) followed

by the addition of Et$_3$N (0.90 mL, 6.84 mmol, 1 eq.). Then 2- bromo-4-

phenylacetophenone (1.88 g, 6.84 mmol, 1 eq.) was added. The reaction

mixture was stirred at room temperature overnight. The solid was filtered, the

filtrate was concentrated, and the residue was purified by column

chromatography on silica gel (hexane/ethyl acetate = 1:1.25 to give **3** (0.45 g,

19%) and **11** (0.27 g, 7%). A clean ^{1}H or ^{13}C NMR spectrum for **11** was not obtained.

For **3**: R_f 0.3 (hexane/ethylacetate = 1.5:1),^{1}H NMR (500 MHz, chloroform-*d*): δ 11.1 (s, OH), 7.99 (m, 2H), 7.80 (m, 2H), 7.75 – 7.66 (m, 2H), 7.63 (m, 2H), 7.52 – 7.39 (m, 1H), 5.39 (s, 2H), 2.55 (m, 2H), 2.43 (m, 2H), 1.78 (m, 4H).^{13}C NMR (125 MHz, chloroform-*d*) δ 191,87, 179.62, 172.74, 146.59, 139.59, 129.00, 128.43, 128.35, 127.47, 127.27, 65.95, 44.97, 33.59, 33.49, 24.24, 24.05.

6-Oxo-6-(2-oxo-1,2-diphenyl ethoxy) hexanoic acid (4) and bis(2-oxo-1, 2-diphenylethyl)adipate (12)

Adipic acid (0.283 g, 1.94 mmol, 1 eq.) was dissolved in EtOAc (10 mL) followed by the addition of Et_3N (0.27 mL, 1.94 mmol, 1 eq.). Then 2-bromo-2-phenylacetophenone (0.5 g, 1.94 mmol, 1 eq.) was added. The mixture was stirred at room temperature overnight and diluted with EtOAc (50 mL), was washed with cooled HCl [1M, 20 mL], washed again with H_2O (320 mL), dried

over Na_2SO_4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane/ethyl acetate = 2/1) to provide **4** (0.75 g, 60%) as a white powder and **12** (0.1 g, 10%).

For **4**: R_f 0.37 (hexane/ethyl acetate = 1:1); ^{1}H NMR (500 MHz, chloroform-*d*) δ 7.96 – 7.90 (m, 2H), 7.54 – 7.30 (m, 8H), 6.86 (s, 1H), 2.59 – 2.49 (m, 2H), 2.47 – 2.41 (m, 2H), 1.74 (br s, 4H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 193.82, 179.34, 172.80, 134.56, 133.49, 129.32, 129.13, 128.78, 128.65, 128.63, 77.59, 33.61, 33.54, 29.69, 24.15, 23.95.

For **12:** ^{1}H NMR (500 MHz, chloroform-*d*) δ 8.00 – 7.88 (m, 4H), 7.52 – 7.41 (m, 6H), 7.44 – 7.27 (m, 10H), 6.86 (m, 2H), 2.57 – 2.48 (m, 2H), 2.50 – 2.41 (m, 2H), 1.81 – 1.70 (m, 4H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 193.78, 172.75, 134.56, 133.52, 133.41, 129.23, 129.06, 128.73, 128.59, 128.58, 77.52, 33.49, 33.49, 24.11, 24.11.

6-((2-methyl-1-oxo-1-phenylpropan-2-yl)oxy)-6-oxohexanoic acid (5) and bis(2-methyl-1-oxo-1-phenylpropan-2-yl)adipate (14)

5   **14**

Adipic acid (0.3 g, 2.05 mmol, 1 eq.) was dissolved in DMF (3 ml). 2-Hydroxy-2-methylpropiophenone (0.312 mL, 2.05 mmol, 1 eq.) was added followed by the addition of 4-*N,N*-dimethylaminopyridine (DMAP) (0.205 g, 0.205 mmol, 0.1 eq.) and *N,N*-diisopropylcarbodimide (DIPCI) (0.48 mL, 3.70 mmol, 1.5 eq.). The mixture was stirred at room temperature for three days. The solid was filtered and washed with hexane/ethyl acetate (1/1). The filtrate was concentrated in *vacuo* and the residue purified by column chromatography on silica gel (hexane /ethylacetate = 3/1) to provide **5** (0.15 g, 19%) as a white powder and **14** (0.17 g, 21%).

For **5**: R_f 0.34 (hexane / ethyl acetate = 2:1); ^{1}H NMR (500 MHz, chloroform-*d*) δ 11.57 (s, 1H), 8.02 – 7.95 (m, 2H), 7.53 – 7.46 (m, 1H), 7.41 (t, *J* = 7.9 Hz, 2H), 2.25 (m, 4H), 1.73 (s, 6H), 1.48 (m, 4H).^{13}C NMR: (125 MHz, chloroform-*d*) δ 199.38, 179.58, 172.28, 134.64, 132.45, 128.45, 128.33, 84.28, 45.00, 34.02, 33.57, 25.37, 23.76, 23.75.

For **14**: ^{1}H NMR (500 MHz, chloroform-*d*) δ 7.96 (m, 4H), 7.41 – 7.33 (m, 6H), 2.14 – 2.06 (m, 4H), 1.69 (s, 12H), 1.26 (m, 4H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 199.19, 172.17, 134.60, 132.42, 128.45, 128.32, 84.20, 33.96, 25.37, 23.58.

6-oxo-6-(2-oxo-2-(2-oxo-2H-chromen-3-yl)ethoxy)hexanoic acid (6) and bis(2-oxo-2-(2-oxo-2*H*-chromen-3-yl)ethyl)adipate (16)

6

+

16

Adipic acid (0.27 g, 1.872 mmole, 1 eq.) was dissolved in EtOAc (7 mL), then

N,N-diisopropylethylamine (0.32 mL, 1.872 mmole, 1 eq.) was added. The

mixture was stirred for 5 min at room temperature. 3-(Bromoacetyl)-coumarin

(0.5 g, 1.872 mmole, 1 eq.) was added, and the mixture was stirred at 80 °C for

overnight. TLC checked until complete reaction followed by a work up: by

filtration of the solid and the concentration of the filtrate under *vacuo*. The residue

was purified by column chromatography on silica gel (hexane/ethyl acetate = 1:4)

to provide compound **6** (0.11 g, 18%) and **16** (0.02 g, 2%).

For **6**: ^{1}H NMR (500 MHz, chloroform-*d*) δ 8.65 (d, *J* = 0.8 Hz, 1H), 7.70 (m, 2H),

7.44 – 7.34 (m, 2H), 5.39 (s, 2H), 2.56 – 2.49 (m, 2H), 2.43 (t, *J* = 6.7 Hz, 2H),

1.77 (m, 4H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 190.16, 178.32, 172.70,

159.19, 155.31, 149.10, 135.13, 130.57, 125.31, 121.92, 118.07, 116.87, 69.15,

33.44, 24.26, 24.01.

Anal.Calcd for **C$_{17}$ H$_{16}$ O$_7$**: C, 61.38; H, 4.81. Found: C, 61.65; H, 4.60.

For **16**: ^{1}H NMR (500 MHz, chloroform-*d*) δ 8.65 (s, 2H), 7.74 – 7.63 (m, 4H), 7.44 – 7.25 (m, 4H), 5.42 (s, 4H), 2.55 (m, 4H), 1.83 (m, 4H).^{13}C NMR (125 MHz, chloroform-*d*) δ 190.15, 172.76, 159.18, 155.30, 149.05, 135.10, 130.57, 125.29, 125.24, 124.84, 121.96, 118.08, 116.85, 69.12, 33.48, 33.23, 29.70, 24.29, 24.19.

Methyl (*S*)-2-((*tert*-butoxycarbonyl) amino)-3-(4-(2-oxopropoxy)phenyl) propanoate (18)

      Compound **17** (0.5 g, 1.69 mmole, 1 eq.) was dissolved in anhydrous acetone (3 mL) and then potassium carbonate (0.5 g, 3.38 mmol, 2 eq.), and chloroacetone (0.134 mL, 1.69 mmol, 1 eq.) were added. The mixture was stirred at 75 ℃ and left for overnight. TLC analysis of the reaction mixture showed no new spot; therefore, potassium iodide (0.56 g, 1.69 mmol, 1 eq.) added. The mixture was refluxed for 6 hours until TLC indicated completion of the reaction. The solid was then filtered and the filtrate concentrated under vacuum. The

residue was purified by column chromatography on silica gel (hexane/ethyl acetate= 1.5:1) to provide compound **18** (0.24 g, 45%).

R_f 0.38 (hexane/ethyl acetate=1.5:1); ^{1}H NMR (500 MHz, chloroform-*d*) δ 7.07 (d, *J* = 8.3 Hz, 2H), 6.85 – 6.77 (m, 2H), 5.21 (d, *J* = 8.0 Hz, 1H), 4.57 – 4.49 (m, 2H), 3.74 – 3.67 (s, 3H), 3.00 (m, 1H), 2.30 (m, 2H), 2.03 (s, 3H), 1.42 (s, 9H). ^{13}C NMR: (125 MHz, chloroform-*d*) δ 205.55, 172.38, 171.03, 156.86, 155.16, 130.53, 129.34, 114.59, 79.74, 77.57, 73.02, 60.34, 54.63, 52.17, 37.37, 28.29, 26.53, 20.98, 14.20.

Methyl (*S*)-2-amino-3-(4-(2-oxopropoxy)phenyl)propanoate hydrochloride (19)

To a solution of **18** (0.1 g, 0.321 mmol, 1 eq.) in EtOAc (1 mL) was added hydrogen chloride solution in diethyl ether (HCl.Et$_2$O) (3 mL). The mixture was stirred at room temperature for 2 h. The mixture was then concentrated *vacuo* and EtOAc (3X, 5 mL) was added, concentrated in *vacuo*, and dried under high

vacuum to provide compound **19** (0.09 g, 97%).^{1}H NMR (500 MHz, DMSO-d_6) δ 8.65 (s, 2H), 7.14 (d, J = 8.2 Hz, 2H), 6.86 (d, J = 8.2 Hz, 2H), 4.80 (s, 2H), 4.22 (t, J = 6.4 Hz, 1H), 3.68 (s, 3H), 3.09 (m, 2H), 2.16 (s, 3H). ^{13}C NMR (125 MHz, DMSO-d_6) δ 204.58, 169.90, 157.48, 130.97, 127.25, 115.01, 72.48, 53.75, 53.06, 35.42, 26.70. The ^{1}H and ^{13}C NMR data were in agreement with those reported in the literature.[16]

3-*O*-(*tert*-butyloxycarbonyemethyl)cholesterol (20)

Sodium hydride (0.827 g, 20.68 mmol, 4 eq.) was added to tetrahydrofuran (20 mL) and then cholesterol (2.0 g, 5.17 mmol, 1 eq.) was added. *Tert*-butyl bromoacetate (4.032 g, 20.68 mmol, 4 eq.) was then added slowly. The mixture was left overnight at 80℃. Water was then added dropwise to the reaction mixture until bubbling stopped, and the solvent was removed in *vacuo*. H$_2$O (50 mL) was added and the mixture extracted with DCM (3 x 50 mL). The combined organic layer was dried over Na$_2$SO$_4$ and concentrated in *vacuo*. The residue was purified by column chromatography on silica gel (hexane/ethyl

acetate = 5:0.3) to provide compound **20** (0.13 g, 67%). R_f 0.34 (hexane /ethyl acetate = 1:1). ^{1}H NMR (500 MHz, chloroform-*d*) δ 5.38 – 5.33 (m, 1H), 4.01 (s, 2H), 3.29 – 3.18 (m, 1H), 2.39 (ddd, *J* = 13.3, 4.8, 2.2 Hz, 1H), 2.31 – 2.22 (m, 1H), 2.05 – 1.89 (m, 3H), 1.90 – 1.77 (m, 2H), 1.62 – 1.50 (m, 3H), 1.50 (s, 9H, 3 CH_3), 1.46 – 1.36 (m, 1H), 1.35 (m, 3H), 1.25 (m, 1H), 1.20 – 1.06 (m, 5H), 1.09 – 1.00 (m, 1H), 1.00 (s, 3H, CH_3), 0.91 (d, *J* = 6.4 Hz, 6H, $2CH_3$), 0.87 (d, 6H, 2 CH_3) 0.67 (s, 3H, CH_3). ^{13}C NMR (125 MHz, chloroform-*d*) δ 170.10, 140.62, 121.81, 81.34, 79.74, 66.04, 56.75, 56.13, 50.12, 42.30, 39.76, 39.51, 38.74, 37.12, 36.82, 36.18, 35.78, 31.93, 31.86, 28.23, 28.11, 28.01, 24.28, 23.82, 22.83, 22.57, 21.05, 19.35, 18.71, 11.85.

3-*O*-carboxymethyl-cholesterol (21)

To a solution of **20** (1.04 g, 1.86 mmol) dissolved in DCM (15 mL) was added trifluoroacetic acid (15 mL) and H_2O (1.5 mL) at 0 ℃. The mixture was stirred at 0 °C for 1 h and then concentrated in *vacuo* to provide compound **21**

(0.48 g, 51%). R_f 0.34 (hexane/ethyl acetate =1:1). ^{1}H NMR (500 MHz, chloroform-d) δ 5.37 (d, J = 5.0 Hz, 1H), 4.16 (s, 2H), 3.31 (m, 1H), 2.42 – 2.35 (m, 2H), 2.28 (m, 2H), 2.05 – 1.94 (m, 4H), 1.94 – 1.83 (m, 4H), 1.74 (m, 1H), 1.62 – 1.51 (m, 7H), 1.51 – 1.49 (m, 2H), 1.49 – 1.42 (m, 4H), 1.40 – 1.31 (m, 6H), 1.26 (d, J = 6.4 Hz, 6H), 1.18 – 1.05 (m, 11H), 1.01 (m, 10H), 0.94 – 0.84 (m, 16H), 0.68 (s, 3H).

Preparation of poly-L-glutamic acid (H$^+$ form)

The commercially available sodium salt of poly-L-glutamic acid (MW 50,000 – 100,000, 300 mg, 1.98 mmol) was dissolved in double distilled water (dd-H_2O) (3 mL) and cooled in an ice bath. Hydrogen chloride solution (1 M, 3 mL) was added drop-wise till pH 1 and the mixture was left to stir for 2 hours. The mixture was then centrifuged for 15 min and the supernatant was removed. The solid was washed with dd-H_2O water until a neutral pH was achieved. The solid was dried in the presence of P_2O_5 under high vacuum overnight to give PGA (H$^+$ form, 210 mg, 82%).

Preparation of m-PGA-Ph-24

Poly-L-glutamic acid (H$^+$ form, 125 mg, 0.97 mmol) was dissolved in dry dimethylformamide (10 mL) and heated in an oil bath at 40°C. Triethylamine (29.4 mg, 40.5 μL, 0.29 mmol) was added and stirred for 5 min, and then bromo-acetophenone (58 mg, 0.29 mmol) was added. The mixture was stirred at 40°C

for 16 h and then cooled to room temperature. A mixture of hexane-ethyl acetate (1:1, v/v, 30 mL) was added slowly to the above reaction mixture to precipitate out the product. The solid was collected after centrifugation (5000 rpm, 10 min) and washed with hexane-ethyl acetate (1:1, v/v, 15 mL×2). The solid was then suspended in ethyl acetate (10 mL) and the mixture stirred for 4 h. After centrifugation and washing with hexane-ethyl acetate (1:1, v/v, 10 mL), the solid was further dried under high vacuum to provide m-PGA-Ph-24 (135 mg) with 24% of the side chains being modified.

^{1}H NMR (500 MHz, trifluoroacetic acid-d): δ7.80 (br s, 0.48H, Ar-H), 7.60 (br s, 0.24H, Ar-H), 7.40 (br s, 0.48H, Ar-H), 5.50 (br s, 0.48 H, OCH$_2$CO), 4.80 (br s, 1H, H-α), 2.50 – 2.80 (2 br s, 2H, H-γ), 1.90 – 2.40 (m, 2H, H-β).

Preparation of m-PGA-Ph-32

Poly-L-glutamic acid (H$^+$ form, 120 mg, 0.93 mmol) was dissolved in dry dimethylformamide (DMF, 9 mL) and heated in an oil bath at 40°C. Triethylamine (37.4 mg, 51.5 μL, 0.37 mmol) was added and stirred for 5 min, and then 2-bromoacetophenone (74 mg, 0.37 mmol) was added. The mixture was stirred at 40°C for 16 h and then cooled to room temperature. A mixture of hexane-ethyl acetate (3:1, v/v, 35 mL) was added slowly to the reaction mixture to precipitate out the product. The solid was collected after centrifugation (5000 rpm, 10 min) and then washed with hexane-ethyl acetate (1:1, v/v, 10 mL, 3X). The solid was then suspended in ethyl acetate and the mixture stirred at room temperature for 16 h. The solid was collected after centrifugation and dried under high vacuum to

provide the crude product (133 mg). The crude product (128 mg) was re-dissolved in dimethylformamide (DMF, 6 mL) and ddH$_2$O (30 ml) was added to give a clear solution. Sodium chloride (3.0 g) was added to the clear solution to facilitate precipitation. The solid was collected after centrifugation and then washed with ddH$_2$O (3X, 10 mL). The fine powder was further dried under high vacuum in the presence of P$_2$O$_5$ for 16 h to provide m-PGA-Ph-32 (100 mg) with 32% of the side chains being modified.

^{1}H NMR (500 MHz, trifluoroacetic acid-d): δ 7.80 (br s, 0.64H, Ar-H), 7.60 (br s, 0.32H, Ar-H), 7.40 (br s, 0.64, Ar-H), 5.50 (br s, 0.64 H, OCH$_2$CO), 4.80 (br s, 1H, H-α), 2.50 – 2.70 (2 br s, 2H, H-γ), 2.05 – 2.30 (m, 2H, H-β).

2,3,4,6-Tetra-*O*-acetyl-*α*/*β*-D-glucopyranose (23)

23

Glucose (10 g, 55.55 mmol, 1 eq.) was dissolved in pyridine (39 mL) and acetic anhydride (28.35 g, 277.77 mmol, 5 eq.) was added. The mixture was stirred at room temperature. Then H$_2$O (30 mL) was added in the mixture and stirred for 30 - 40 min. Cold H$_2$O (500 mL) was added, extracted with EtOAc (3X, 200 mL), and washed with HCl [6M, 100 ml] checked pH= 1-2, washed again with saturated NaHCO$_3$ (100 mL) checked pH= 8, dried over Na$_2$SO$_4$, and concentrated under

vacuo to provide compound **22** (23 g, 94%). **22** (10 g, 23.89 mmol, 1 eq.) was

dissolved in DMF, and ammonium carbonate (5 g, 47.79 mmol, 2 eq.) was

added. The mixture was stirred at 30 ℃ for 20 h. After that was added $CHCl_3$ (50

mL) and cooled HCl [1M, 50 mL], extracted with $CHCl_3$ (2X 50 mL). The organic

layer was washed with saturated $NaHCO_3$ (20 mL) and then with H_2O (40 mL),

dried over Na_2SO_4, concentrated under *vacuo*. The residue was purified by

column chromatography on silica gel (hexane/ethyl acetate = 1:1) to provide

compound **23** (3.16 g, 43%).

2,3,4,6-Tetra-*O*-acetyl-α-D-glucopyranosyl trichloroacetimidate (24)

     23 (1.3 g, 3.72 mmol, 1 eq.) was dissolved in anhydrous DCM (10mL) and

trichloroacetonitrile (CCl_3CN) (1.86 mL, 18.6 mmol, 5 eq.) and 1,8-diazabicyclo

[5.4.0] undec-7-ene (DBU) (0.1 mL, 0.744 mmol, 0.2 eq.) were added. The

mixture was stirred at room temperature for 3 h. The mixture was concentrated

under *vacuo* and the residue was purified by column chromatography on silica

gel (hexane/ethyl acetate/ Et₃N = 2:1:0.5%) to provide compound **24** (1.4 g, 90%).

2-(2,3,4,6-Tetra-*O*-acetyl-β-D-glucopyranosyloxy)-naphthalene-1,4-dione (26) and 4-(2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranosyloxy)-naphthalene-1,2-dione (27)

26   **27**

To a solution of **24** (0.81 g, 1.79 mmol, 1.2 eq.) in anhydrous THF (7 mL) and 2-hydroxy-1,4-naphthoquinone (lawsone) (0.32 g, 1.49 mmol, 1 eq.) in anhydrous DCM (5 mL) at room temperature was added a solution of boron trifluoride – diethyl etherate (BF₃.O(Et)₂) in DCM (0.1 M, 1.25 mL, 0.537 mmol, 0.3 eq.). The mixture was stirred for 4 h. The reaction was checked by TLC until completion and followed by a work-up: quenched with saturated aqueous NaCO₃H (20 mL), extracted with EtOAc (1X, 50 ml) then (3X, 10 mL), dried with Na₂SO₄, concentrated, purified by column chromatography on silica gel (toluene/acetone = 9:1, then 6:1), and concentrated to provide compound **26**

(0.59 g, 65%) and **27** (0.27 g, impure). Compound **27** was not clean and was re-purified by column chromatography on silica gel (toluene/acetone = 5:1) to provide 0.16 g (18%) of pure material.

For **26:** ^{1}H NMR (500 MHz, chloroform-*d*) δ 8.19 – 8.03 (m, 1H), 7.82 – 7.69 (m, 1H), 6.43 (s, 1H), 5.43 – 5.31 (m, 2H), 5.23 (d, *J* = 7.5, 1H), 5.17 (dd, *J* = 10.1, 8.8Hz, 1H), 4.27 (m, 1H), 4.21 (m, 1H), 3.97 (m, 1H), 2.19 – 2.00 (m, 12H, 4 CH$_3$).^{13}C NMR: (125 MHz, chloroform-*d*) δ 207.03, 184.91, 178.78, 170.55, 170.16, 169.35, 169.09, 157.29, 135.17, 134.32, 133.74, 133.12, 131.60, 130.99, 126.72, 126.61, 126.46, 126.15, 114.74, 97.65, 77.36, 77.10, 76.85, 75.79, 72.80, 72.18, 70.46, 70.35, 67.90, 66.45, 61.69, 61.31, 30.94, 29.69, 20.67, 20.60, 20.58, 20.35.

For **27:** ^{1}H NMR (500 MHz, chloroform-*d*) δ 8.10 (d, *J* = 7.5 Hz, 1H), 7.73 (m, 2H), 7.64 (m, 1H), 6.10 (s, 1H), 5.52 (m, 2H), 5.19 (d, *J* = 8.2 Hz, 1H), 4.34 (dd, *J* = 12.5, 6.0 Hz, 1H), 4.27 – 4.16 (m, 1H), 4.11 – 4.01 (m, 1H), 2.16 – 2.01 (m, 12H, 4 CH$_3$).^{13}C NMR: (125 MHz, chloroform-*d*) δ 207.10, 192.44, 179.62, 178.59, 170.54, 169.98, 169.42, 169.41, 165.38, 135.53, 134.48, 131.89, 131.18, 130.34, 129.75, 129.54, 129.00, 128.54, 127.61, 126.97, 124.87, 106.33, 97.17, 72.90, 71.99, 70.31, 68.48, 67.89, 67.15, 61.50, 44.99, 30.95, 29.71, 20.77, 20.64, 20.63, 20.58, 20.57.

1,2,3,4,6-Penta-*O*-trimethylsilyl-α/β-D-glucopyranose (30)

To a dissolved solution of glucose (1.033 g, 5.742 mmol, 2 eq.) in DMF (25 mL) was added Et₃N (3.18 g, 31.58 mmol, 5.5 eq.) and trimethylsilyl chloride (TMS-Cl) (4.76 g, 31.58 mmol, 5.5 eq.). The mixture was stirred at room temperature. Pentane (100 mL) and ice (100 mL) was added to the reaction mixture. The organic layer was separated and the aqueous layer extracted with pentane (3x 50 mL). The combined organic layer was washed with H_2O (2X, 100 mL) and then with saturated aqueous NaCl solution (2X, 100 mL), dried over Na_2SO_4, and concentrated to provide **30** (3.5 g, 88%).

2,3,4,6-Tetra-*O*-trimethylsilyl-α-D-glucopyranosyl iodide (31)

To a solution of **30** (3.5 g, 5.74 mmol, 1 eq.) in anhydrous DCM (15 mL) was added trimethylsilyl iodide (TMS-I) (6.3 mL, 6.31mmol, 1.1 eq.). The reaction mixture was stirred at room temperature for 10 min. The mixture was concentrated under *vacuo* at less than 30°C and the remaining liquid was co-

distilled with benzene (3x), dried under high *vacuo* to give **31** (4.5 g, 74%).

2-(2,3,4,6-Tetra-*O*-trimethylsilyl-α/β-D-glucopyranosyloxy)-naphthalen-1,4-dione (34) and 4-(2,3,4,6-tetra-*O*-trimethylsilyl-α/β-D-glucopyranosyloxy)-naphthalen-1, 2-dione (35)

2-Hydroxy-1,4-naphthaquinone (0.9 g, 5.22 mmol, 1 eq.) was dissolved in THF (10 mL) and sodium bis(trimethylsilyl)amide (NaN(SiMe$_3$)$_2$) (5.2 mL, 28.46 mmol, 5.5 eq.) was added. The mixture was stirred at room temperature for 10 min to generate the corresponding enolates of lawsone.

15-Crown-5 (1.14 g, 5.22 mmol, 1 eq.) was added and the mixture was stirred at room temperature for 4 h. The mixture was concentrated under *vacuo* and DCM (60 mL) was added. The organic layer was washed with half saturated aqueous NaCl solution (2x 20 mL), dried over Na$_2$SO$_4$, and concentrated, to provide crude glycosylated product **34** and **35** (3.7 g). The product was not purified but used directly for the trials of deprotection reaction.

2-Hydroxy-3- {[(2-hydroxyethyl)amino]methyl}naphthalene-1,4-dione (45)

2-Hydroxy-1,4-naphthoquinone (0.1 g, 0,57 mmol, 1.0 eq.) was dissolved in anhydrous ethanol and then ethanolamine (0.035 g, 0.57 mmol, 1.0 eq.) was added. The mixture was stirred for 5 min at 45℃. Formaldehyde (0.017 g, 0.57 mmol 1.0 eq.) was added and the mixture was stirred for 6 h at 45℃. The solid was filtered to provide compound **45** (0.109 g, 73%). ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.32 – 8.28 (br s, 1H), 7.95 (dd, J = 7.7, 1.2 Hz, 1H), 7.82 (dd, J = 7.6, 1.3 Hz, 1H), 7.72 (td, J = 7.5, 1.3 Hz, 1H), 7.58 (td, J = 7.5, 1.3 Hz, 1H), 4.02 (s, 2H), 3.67 (t, J = 5.4 Hz, 2H), 2.96 (t, J = 5.4 Hz, 2H).^{13}C NMR: (125 MHz, DMSO-d_6) δ 184.96, 182.29, 179.11, 172.14, 135.41, 134.04, 133.97, 133.65, 132.11, 131.98, 131.23, 131.04, 125.75, 125.72, 125.60, 125.48, 125.45, 107.76, 107.09, 56.66, 48.28, 42.08.

2-Hydroxy-3-{[(3-hydroxypropyl)amino]methyl}naphthalene-1,4-dione (**46**)

2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in anhydrous ethanol and then 3-amine-1-propanol (0.1 mL, 0.55 mmol, 1.1 eq.) was added. The mixture was stirred for 20 min at room temperature. Formaldehyde (0.1 mL, 0.55 mmol, 1.1 eq.) was added and the mixture was stirred at room temperature overnight. The product was filtered out to provide orange solid compound **46** (0.15 g, 94%).

^{1}H NMR (500 MHz, DMSO-d_6) δ 8.17 (br s, 1H), 7.94 (dd, J = 7.7, 1.3 Hz, 1H), 7.82 (dd, J = 7.6, 1.3 Hz, 1H), 7.70 (td, J = 7.5, 1.4 Hz, 1H), 7.57 (td, J = 7.5, 1.3 Hz, 1H), 4,089 (s, 1 H), 3.94 (s, 2H), 3.47 (t, J = 6.0 Hz, 2H), 2.93 (t, J = 7.5 Hz, 2H),1.82 – 1.72 (m, 2H).^{13}C NMR: (125 MHz, DMSO-d_6) δ 185.11, 178.91, 172.15, 135.58, 134.08, 132.08, 131.04, 125.80, 125.55, 108.01, 58.78, 44.70, 42.20, 28.94.

2-Hydroxy-3-{[(bis(2-hydroxyethyl)amino]methyl}naphthalene-1,4-dione (47)

2-Hydroxy-1,4-naphthaquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in anhydrous ethanol and then diethanol amine (0.05 mL, 0.57 mmol, 1.0 eq.) was added to react for 20 min at room temperature. Formaldehyde (0.1 mL, 0.57 mmol, 1.0 eq.) was added and the mixture was stirred at 45 ℃ overnight. The product was filtered out to provide the orange solid compound **47** (0.113 g, 98%).

2-Hydroxy-3-{[(2-hydroxyethyl)amino]phenylmethyl}naphthalene-1, 4-dione (48)

2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in anhydrous ethanol and ethanolamine (0.038 mL, 0.6 mmol,1.1 eq.) was added to react for 20 min at room temperature. Benzaldehyde (0.064 mL, 0.6 mmol, 1.1 eq.) was added and the mixture was stirred at room temperature. The product was filtered out to provide the orange solid compound **48** (0.16 g, 86%).

^{1}H NMR: (500 MHz, DMSO-d_6) δ 9.82 (br s, 1H), 9.18 (br s, 1H), 7.93 (dd, J = 7.7, 1.3 Hz, 1H), 7.83 (dd, J = 7.6, 1.3 Hz, 1H), 7.72 (td, J = 7.6, 1.4 Hz, 1H), 7.64 – 7.56 (m, 3H), 7.37 (m, 2H), 7.35 – 7.28 (m, 1H), 5.59 (s, 1H), 5.13 (s, 1H), 3.68 – 3.58 (m, 2H), 3.00 (m, 2H). ^{13}C NMR: (125 MHz, DMSO): δ 184.80, 178.78, 171.03, 138.96, 135.10, 134.24, 131.93, 131.35, 128.88, 128.42, 128.29, 125.83, 125.57, 111.86, 59.39, 56.99, 56.51, 48.29.

2-Hydroxy-3-{[(2-hydroxypropyl)amino]phenylmethyl}naphthalene-1,4-dione (49)

2-Hydroxy-1,4-naphthoquinone (0.1 g, 0.57 mmol, 1.0 eq.) was dissolved in anhydrous ethanol and then 3-amine-1-propanol (0.041 mL, 0.63 mmol, 1.1

eq.) was added to reacting for 20 min at room temperature. Benzaldehyde (0.07 mL, 0.63 mmol, 1.1 eq.) was added and the mixture was stirred at room temperature overnight. The product was filtered out to provide orange solid compound **49** (0.198 g, 97%). ^{1}H NMR (500 MHz, DMSO-d_6) δ 9.78 (br s, 1H), 9.00 (br s, 1H), 7.93 (d, J = 7.7 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.72 (t, J = 7.6 Hz, 1H), 7.65 – 7.56 (m, 3H), 7.37 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 5.53 (s, 1H), 4.78 (s, 1H), 3.47 (m, 2H), 3.00 (m, 1H), 2.93 (m, 1H), 1.80 (m, 2H).^{13}C NMR: (125 MHz, DMSO-d_6) δ 184.83, 178.72, 171.03, 139.14, 135.17, 134.21, 131.97, 131.30, 128.82, 128.32, 128.16, 125.81, 125.56, 111.67, 59.29, 58.96, 44.62, 29.14.

Tert-butyl-(3-hydroxypropyl)carbamate (50)

3-Amino-1-propanol (2.1 g, 29.29 mmol, 1.0 eq.) and triethylamine (3.25 g, 32.21 mmol, 1.1 eq.) were dissolved in $CHCl_3$ (20 mL). Di-*tert*-butyldicarbonate (7.0 g, 32.21 mmol, 1.1 eq.) dissolved in 10 ml $CHCl_3$ was added dropwise to the mixture. The mixture was stirred at room temperature overnight. The mixture was then extracted with water (3x 10mL) and the organic layer dried over Na_2SO_4, and concentrated under *vacuo*. The residue was purified by column

chromatography on silica gel (hexane/ethylacetate= 2:1) and concentrated to provide compound **50** (3.69 g, 71%).

3-*tert*-Butoxycarbonylamino-prop-1-yl 2,3,4,6-tetra-*O*-acetyl-β-D-glucopyranoside (51)

50 (1.49 g, 3.28 mmol, 1.0 eq.) and **24** (0.574 g, 3.28 mmol, 1.0 eq.) were dissolved in DCM (3 mL). BF_3OEt_2 in DCM solution (0.1 M, 0.9 mL) was added to the reaction mixture under argon. This reaction mixture was stirred at room temperature overnight. Sodium bicarbonate solution (20 mL) was added and the mixture was extracted with dichloromethane (3 x 20 mL). The organic layer was dried with Na_2SO_4, concentrated, and the residue purified by column chromatography on silica gel (hexane /ethyl acetate= 1:1) to provide compound **51** (0.49 g, 29 %) which was obtained as slightly impure material. ^{1}H NMR (500 MHz, chloroform-*d*): δ 5.71 (m, 2H), 5.30 (m, 1H), 5.17 (m, 1H), 5.11 (m, 1H), 4.34 (m, 1H), 4.15 (m, 2H), 3.95 – 3.84 (m, 1H), 3.78 – 3.70 (m, 1H), 3.72 – 3.65 (m, 1H), 3.45 – 3.34 (m, 1H), 3.37 – 3.23 (m, 1H), 2.16 – 2.04 (m, 12H), 1.88 – 1.75 (m, 2H).

3-Amino-prop-1-yl β-D-glucopyranoside (52)

51 (0.16 g, 0.316 mmol, 1 eq.) was deprotected to remove the acetyl

groups by dissolving in anhydrous methanol (3 mL), followed by adding catalytic

amount of sodium methoxide solution to adjust the reaction mixture to have pH =

9. The progress of the reaction was monitored by TLC until the reaction was

complete and followed by a work up: Resin-IR-69 was added until the pH = 7,

followed by filtration and concentration in *vacuo*, purified by column

chromatography on silica gel (chloroform/methanol = 3:0.5) to provide the

deacetylated intermediate (0.1 g, 94%). The deacetylated intermediate was

dissolved in trifluoroacetic acid (TFA) (3 mL) and water (0.2 mL) and stirred at rt

for 30 min when TLC showed the completion of reaction. The reaction was

worked up by concentration under *vacuo* to give free amine **52** (0.045 g, 71%) as

TFA salt.

**2-Hydroxy-3-(1-β-D-glucopyranosyloxy-prop-3-yl)-aminomethyl-
naphthalene-1,4-dione (53)**

52 (0.45 g, 0.189 mmol, 1.0 eq.) was dissolved in ethanol (3 mL), followed by the

addition of diisopropylethylamine (42.51 mg, 0.189 mmol, 1.0 eq.). The mixture

was stirred at room temperature for 5 min under argon, and 2-hydroxy-1,4-

naphthoquinone (32.88 g, 0.189 mmol, 1.0 eq.) was added. The mixture was

stirred at room temperature for 10 min under argon. After that formaldehyde (5.6

mg, 0.189 mmol, 1.0 eq.) was added, and the reaction mixture was stirred at

room temperature overnight. Solvent was then removed and the residue was

purified by repeated column chromatography (chloroform/methanol= 3:2) and

(chloroform/methanol/ H_2O = 3:2:0.1) to give **53** (0.01 g, 14%) which was slightly

impure. ^{1}H NMR (500 MHz, chloroform-*d*) δ 7.97 (d, *J* = 7.6 Hz, 1H), 7.88 (m,

1H), 7.63 (m, 1H), 7.49 (m, 1H), 4.33 (d, *J* = 7.0 Hz, 1H), 4.11 (m, 2H), 3.90 –

3.83 (m, 3H), 3.77 (m, 2H), 3.52 – 3.41 (m, 4H), 2.60 (m, 1H), 1.31 – 1.23 (m,

2H).

6. References

1. Singh, Y., Palombo, M., and Sinko, P. **(2008).** Recent Trends in Targeted Anticancer Prodrug and Conjugate Design. *Current Medicinal Chemistry*, *15* (18), 1802-1826.

2. Skeel, RT., Editor. Handbook of Cancer Chemotherapy. Lippincott Williams and Wilkins; USA: (**2007)**.

3. Jiang, Y., Han, J., Yu, C., Vass, S., Searle, P., Browne, P., Knox, R., J., and Hu., L. **(2006)**. Design, Synthesis, and Biological Evaluation of Cyclic and Acyclic Nitrobenzylphosphoramide Mustards for *E. coli* Nitroreductase Activation. *Journal of Medicinal Chemistry*, *49*(14), 4333-4343.

4. Bala, I., Hariharan, S., and Kumar, M. **(2004)**. PLGA Nanoparticles in Drug Delivery: The State of the Art. *Critical Reviews in Therapeutic Drug Carrier Systems*, *21*(5), 387-422.

5. Du, J,-Z., Du, X.-J, Mao, C,-Q., and Wang, J. **(2011)**. Tailor-Made Dual pH-Sensitive Polymer–Doxorubicin in Nanoparticles for Efficient Anticancer Drug Delivery. *Journal of the American Chemical Society*, *133*(44), 17560-17563.

6. Zee-Cheng, R. K., and Cheng, C. C. **(1988)**. Delivery of anticancer drugs. *Methods and findings in Experimental and Clinical Pharmacology*, *11*(7-8), 439-529.

7. Ahmad, Z., and Khuller, G. **(2008)**. Alginate-based sustained release drug delivery systems for tuberculosis. *Expert Opinion on Drug Delivery*, *5*(12), 1323-1334.

8. Jain, K. **(2008)**. Drug Delivery Systems - An Overview. *Drug Delivery Systems*, 1-50.

9. Shirke, S., Shewale, S., and Satpute, M. **(2015)**. Prodrug design: an overview. *International Journal of Pharmaceutical Chemical and Biological Sciences,* 5(1), 232-241.

10. Singh, Y., Palombo, M., and Sinko, P. **(2008)**. Recent Trends in Targeted Anticancer Prodrug and Conjugate Design. *Current Medicinal Chemistry*, *15*(18), 1802-1826.

11. Chen, Y., and Hu, L. **(2009)**. Design of anticancer prodrugs for reductive activation. *Medicinal Research Reviews*, *29*(1), 29-64.

12. Wei, M., Gao, Y., Li, X., and Serpe, M.J. **(2016)**. Stimuli-responsive polymers and their applications. *Polymer Chemistry*, (8), 127-143.

13. Dai, S., Ravi, P., and Tam, K. **(2008)**. pH-responsive polymers: synthesis, properties and applications. *Soft Matter*, *4*(3), 435- 449.

14. Irie, M. **(1990)**. Properties and applications of photoresponsive polymers. *Pure and Applied Chemistry*, *62*(8).,1495-1502.

15. Tanabe, K., Mimasu, Y., Eto, A., Tachi, Y., Sakakibara, S., Mori, M., and Nishimoto, S. I.**(2003)**. One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs. *Bioorganic and Medicinal Chemistry*, *11*(21), 4551–4556.

16. Tanabe, K., Ebihara, M., Hirata, N., and Nishimoto, S. I. **(2008)**. Radiolytic one-electron reduction characteristics of tyrosine derivative caged by 2-oxopropyl group. *Bioorganic and Medicinal Chemistry*

Letters, *18*(23), 6126–6129.

17. Shibamoto,Y., Sugie, C., Ito, M., and Ogino, H. **(2004)**. Review The Japanese experiences with hypoxia-targeting pharmacoradiotherapy : from hypoxic cell sensitisers to radiation-activated prodrugs, *Expert Opinion on Pharmacotherapy,* 2459–2467.

18. Naylor, M., Swann, E., Everett, S., Jaffar, M., Nolan, J., and Robertson, N., Lockyer, S., Patel, K., Dennis, M., Stratford, M., Wardman, P., Adams, G., Moody, C., and Stratford, I. **(1998)**. Indolequinone Antitumor Agents: Reductive Activation and Elimination from (5-Methoxy-1-methyl-4, 7-dioxoindol-3-yl) methyl Derivatives and Hypoxia-Selective Cytotoxicity in Vitro. *Journal of Medicinal Chemistry*, *41*(15), 2720-2731.

19. Maeda, H., Seymour, L., and Miyamoto, Y. **(1992**). Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. *Bioconjugate Chemistry*, *3*(5), 351-362.

20. Melancon, M. P., and Li, C. **(2011)**. Multifunctional Synthetic Poly (l-Glutamic Acid)–Based Cancer Therapeutic and Imaging Agents. *Molecular imaging*, *10*(1), 7290-2011.

21. Chai, H., Kiew, L., Chin, Y., Norazit, A., Mohd Noor, S., Lo, Y., Looi, C., Lau, Y., Lim, T., Wong, W., Abdullah, N., Abdul Sattar, M., Johns, E., Chik, Z., and Chung, L. **(2017)**. Renal targeting potential of a polymeric drug carrier, poly-L-glutamic acid, in normal and diabetic rats. *International Journal of Nanomedicine*, *12*, 577-591.

22. Ogunleye, A., Irorere, V., Williams, C., Hill, D., Bhat, A., and Radecka, I.

(2015). Poly-γ-glutamic acid: production, properties and application. *Microbiology*, *161*(1), 1-17.

23. Shih, I., and Van, Y. **(2001)**. The production of poly-(γ-glutamic acid) from microorganisms and its various applications. *Bioresource Technology*, *79*(3), 207-225.

24. Li, C. **(2002)**. Poly (l-glutamic acid)–anticancer drug conjugates. *Advanced Drug Delivery Reviews*, *54*(5), 695-713.

25. Ye, F., Ke, T., Jeong, E., Wang, X., Sun, Y., Johnson, M., and Lu, Z. **(2006).** Noninvasive Visualization of in Vivo Drug Delivery of Poly (l-glutamic acid) Using Contrast-Enhanced MRI. *Molecular Pharmaceutics*, *3*(5), 507-515.

26. Petronzi C, Festa M, Peduto A, Castellano M, Marinello J, Massa A, Capasso A, Capranico G, La Gatta A, De Rosa M, Caraglia M, and Filosa R. **(2013)**. Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation, *Journal of Experimental & Clinical Cancer Research*, 32(1):24.

27. Ogata, T., Yoshida, T., Shimizu, M., Tanaka, M., Fukuhara, C., Ishii, J., Nishiuchi, A., Inamoto, K., and Kimachi,T. **(2015)**. Unusual *O*-Alkylation of 2-Hydroxy-1, 4- naphthoquinone Utilizing Alkoxymethyl Chlorides, *Chemical and Pharmaceutical Bulletin, 63*(7), 485–488.

28. Nematollahi, A., Aminimoghadamfarouj, N., and Wiart,C. **(2012)**. Reviews on 1,4-naphthoquinones from *Diospyros* L. *Journal of Asian Natural Products Research*, 1477-2213.

29. López López, L. I., Nery, Flores, Daniel, S., Silva Belmares, S. Y., and Sáenz Galindo, A. **(2014)**. Naphthoquinones: biological properties and synthesis of lawsone and derivatives-a structured review. *Vitae*, *21*(3), 248-258.

30. Ashnagar A, and Shiri A. **(2011)**. Isolation and characterization of 2-hydroxy-1,4-naphthoquinone (lawsone) from the powdered leaves of henna plant marketed in Ahwaz city of Iran. *International Journal of ChemTech Research*, 3 (4): 1941-1944.

31. Rahmoun, M. N., Benabdallah, M., Villemin, D., Boucherit, K., Mostefa-Kara, B., Ziani-Cherif, C., and Choukchou-Braham, N. **(2010)**. Antimicrobial screening of the Algerian *Lawsonia inermis* (henna). *Der Pharma Chemica*, *2*(6), 320-326.

32. Jordao, A. K., Vargas, M. D., Pinto, A. C., da Silva, F. D. C., and Ferreira, V. F. **(2015)**. Lawsone in organic synthesis. *RSC Advances*, *5*(83), 67909-67943.

33. Jacob, C., Klotz, L., and Hou, X. **(2014)**. 1,4-Naphthoquinones: From Oxidative Damage to Cellular and Inter-Cellular Signaling, *Molecules,* 19 (1), 14902-14918.

34. Gutierrez, P. **(2000)**. The metabolism of quinone-containing alkylating agents free radical production and measurement. *Frontiers in Bioscience*, *5*(3), d629-638.

35. Hooker, S. **(1892)**. LVII. —the constitution of "lapachic acid" (lapachol) and its derivatives. *Journal of the Chemical Society, Transactions, 61*(0), 611-650.

36. Fieser.F.L, and Martin.E.L. **(1941)**. 2-Hydroxy-1, 4 Naphthoquinone. *Organic Syntheses*, 21, 56.

37. Pelageev, D., Dyshlovoy, S., Pokhilo, N., Vladimir, D., Ksenia, B., Amsberg, G.,K., Bokemeyer, C., Fedorov, S., Honecker, F., and Anufriev, V. **(2014)**. Quinone–carbohydrate nonglucoside conjugates as a new type of cytotoxic agents: Synthesis and determination of in vitro activity. *European Journal of Medicinal Chemistry*, *77*, 139-144.

38. Calvaresi, E. and Hergenrother, P. **(2013)**. Glucose conjugation for the specific targeting and treatment of cancer. *Chemical Science*, *4*(6), 2319-2333.

39. Cao, H., Hwang, J., and Chen, X. **(2011)**. 14. Carbohydrate-Containing Natural Products in Medicinal Chemistry. *Opportunity, Challenge and Scope of Natural products in Medicinal Chemistry*, 411-431.

40. Hirata, N., Fujisawa, Y., Tanabe, K., Harada, H., Hiraoka, M., and Nishimoto, S. **(2009)**. Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. *Organic Biomolecular Chemistry*, *7*(4), 651–654.

41. Bozzuto, G., and Molinari, A. **(2015)**. Liposomes as nanomedical devices. *International Journal of Nanomedicine*,10 (1) 975-999.

42. Kapadia, G., Rao, G., Sridhar, R., Ichiishi, E., Takasaki, M., Suzuki, N.,

Konoshime, T., Iide, A., and Tokuda, H. **(2013)**. Chemoprevention of Skin Cancer: Effect of *Lawsonia inermis* L. (Henna) Leaf Powder and its Pigment Artifact, Lawsone in the Epstein- Barr Virus Early Antigen Activation Assay and in Two-Stage Mouse Skin Carcinogenesis Models. *Anti-Cancer Agents in Medicinal Chemistry*, *13*(10), 1500-1507.

43. Pradhan, R., Dandawate, P., Vyas, A., Padhye, S., Biersack, B., Schobert, R., Ahmad, A., and Sarkar, FH. **(2012)**. From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna. *Current Drug Targets*, *13*(14), 1777-1798.

44. Singh, D., and Luqman, S. **(2014)**. Lawsonia inermis (L.): A perspective on anticancer potential of Mehndi/Henna. *Biomedical Research and Therapy*, *1*(4) 112-120.

45. Schmidt, R., and Michel, J. (**1980**). Facile Synthesis of α- and β-*O*-Glycosyl Imidates; Preparation of Glycosides and Disaccharides. *Angewandte Chemie International Edition in English*, *19*(9), 731-732.

46. Ellervik, U., and Magnusson, G. **(1997)**. Guanidine/guanidinium nitrate; a mild and selective *O*-deacetylation reagent that leaves the *N*-Troc group intact. *Tetrahedron Letters*, *38*(9), 1627-1628.

47. Bhat, A., and Gervay-Hague, J. **(2001)**. Efficient Synthesis of β-Cyanosugars Using Glycosyl Iodides Derived from Per-*O*- Silylated Mono- and Disaccharides. *Organic letters*, *3* (13), 2081-2084.

48. Hooker, S. **(1936)**. Additions and Corrections - Condensation of Aldehydes with Hydroxy-naphthoquinone. Synthesis of Hydrolapachol. *Journal of the American Chemical Society*, *58*(12), 2661-2661.

49. Souza, N. B. D., de Andrade, I. M., Carneiro, P. F., Jardim, G. A., de Melo, I. M., da Silva Júnior, E. N., and Krettli, A. U. (**2014**). Blood shizonticidal activities of phenazines and naphthoquinoidal compounds against *Plasmodium falciparum in vitro* and in mice malaria studies. *Memórias do Instituto Oswaldo Cruz*, *109*(5), 546-552.

7. Appendix

7.1. ^{1}H and ^{13}C Spectra of Corresponding Compounds

1   ^{1}H NMR spectrum of **1**

2   ^{13}C NMR spectrum of **1**

3   ^{1}H NMR spectrum of **9**

4   ^{13}C NMR spectrum of **9**

5   ^{1}H NMR spectrum of **2**

6   ^{13}C NMR spectrum of **2**

7   ^{1}H NMR spectrum of **3**

8   ^{13}C NMR spectrum of **3**

9   ^{1}H NMR spectrum of **4**

10   ^{13}C NMR spectrum of **4**

11   ^{1}H NMR spectrum of **12**

12   ^{13}C NMR spectrum of **12**

13   ^{1}H NMR spectrum of **5**

14   ^{13}C NMR spectrum of **5**

15   ^{1}H NMR spectrum of **14**

16   ^{13}C NMR spectrum of **14**

17   ^{1}H NMR spectrum of **6**

18   ^{13}C NMR spectrum of **6**

19   ^{1}H NMR spectrum of **16**

20   ^{13}C NMR spectrum of **16**

^{1}H NMR spectrum of **1**

^{13}C NMR spectrum of **1**

^{1}H NMR spectrum of **9**

^{13}C NMR spectrum of **9**

^{1}H NMR spectrum of **2**

^{13}C NMR spectrum of **2**

^{1}H NMR spectrum of **3**

^{13}C NMR spectrum of **3**

¹H NMR spectrum of **4**

^{13}C NMR spectrum of **4**

^{1}H NMR spectrum of **12**

^{13}C NMR spectrum of **12**

^{1}H NMR spectrum of **5**

^{13}C NMR spectrum of **5**

^{1}H NMR spectrum of **14**

^{13}C NMR spectrum of **14**

^{1}H NMR spectrum of **6**

^{13}C NMR spectrum of **6**

^{1}H NMR spectrum of **16**

^{13}C NMR spectrum of **16**

^{1}H NMR spectrum of **18**

^{13}C NMR spectrum of **18**

^{1}H NMR spectrum of **19**

^{13}C NMR spectrum of **19**

^{1}H NMR spectrum of **20**

^{13}C NMR spectrum of **20**

^{1}H NMR spectrum of **21**

^{1}H NMR spectrum of m-PGA-Ph-24

m-PGA-Ph-32

^{1}H NMR spectrum of m-PGA-32

^{1}H NMR spectrum of **26**

^{13}C NMR spectrum of **26**

^{1}H NMR spectrum of **27**

^{13}C NMR spectrum of **27**

^{1}H NMR spectrum of **45**

^{13}C NMR spectrum of **45**

^{1}H NMR spectrum of **46**

^{13}C NMR spectrum of **46**

^{1}H NMR spectrum of **48**

^{13}C NMR spectrum of **48**

^{1}H NMR spectrum of **49**

^{13}C NMR spectrum of **49**

^{1}H NMR spectrum of **53**